

# Schizophrenia: Genetics, neurological mechanisms, and therapeutic approaches

Debbie Xiu En Lim<sup>1,2,3,4</sup>, Shi Yun Yeo<sup>4</sup>, Zhen You Ashley Chia<sup>4</sup>, Aaron Zefrin Fernandis<sup>4</sup>, Jimmy Lee<sup>5,6</sup>, John Jia En Chua<sup>1,2,3,7,\*</sup>

<https://doi.org/10.4103/NRR.NRR-D-24-01375>

Date of submission: November 6, 2024

Date of decision: March 4, 2025

Date of acceptance: April 7, 2025

Date of web publication: May 6, 2025

## From the Contents

Introduction

Search Strategy

Clinical Course, Trajectories, and Diagnosis of Schizophrenia

Neurotransmitter Systems Driving Positive, Negative, and Cognitive Symptoms

Genes Implicated in Schizophrenia Identified by Recent Genome-Wide Association Study and Their Associated Molecular Pathways

Emerging Therapeutics for Schizophrenia and Treatment-Resistant Schizophrenia

Outlook and Conclusion

## Abstract

Schizophrenia is a complex psychiatric disorder marked by positive and negative symptoms, leading to mood disturbances, cognitive impairments, and social withdrawal. While anti-psychotic medications remain the cornerstone of treatment, they often fail to fully address certain symptoms. Additionally, treatment-resistant schizophrenia, affecting 30%–40% of patients, remains a substantial clinical challenge. Positive, negative symptoms and cognitive impairments have been linked to disruptions in the glutamatergic, serotonin, GABAergic, and muscarinic pathways in the brain. Recent advances using genome-wide association study and other approaches have uncovered a significant number of new schizophrenia risk genes that uncovered new, and reinforced prior, concepts on the genetic and neurological underpinnings of schizophrenia, including abnormalities in synaptic function, immune processes, and lipid metabolism. Concurrently, new therapeutics targeting different modalities, which are expected to address some of the limitations of anti-psychotic drugs currently being offered to patients, are currently being evaluated. Collectively, these efforts provide new momentum for the next phase of schizophrenia research and treatment.

**Key Words:** neuroinflammation; neuropsychiatric disorders; neurotransmitter pathways; schizophrenia risk genes; treatment resistance

## Introduction

Schizophrenia (SCZ) is a complex psychiatric disorder characterized by a broad range of symptoms, including positive symptoms (hallucinations, delusions, disorganized speech, and behavior), negative symptoms (deficits in motivation and pleasure, and expression), and cognitive impairments (deficits in attention, working memory, and executive function) (Jauhar et al., 2022; **Figure 1**). Globally, SCZ accounts for a substantial disease burden with 13.4 million years of life lived with disability (95% UI: 9.9–16.7) based on Global Burden of Disease (GBD) study in 2016 (Murray et al., 2020). A recent comprehensive analysis of 396 medical conditions, which included major mental health disorders, reported an increase in the burden of SCZ experienced by individuals between the ages of 25 and 49 (Diseases and Injuries, 2020). A follow-up report from the GBD 2019 Mental Disorders Collaborators group, which specifically examined twelve mental disorders, ranked SCZ fifth as a cause of burden in individuals aged 15 to 24 years. Among individuals aged 25 to 69 years, SCZ was ranked third (following depressive and anxiety disorders,

which have higher prevalence), and fourth among individuals over 70 years old (Collaborators, 2022).

The manifestation of SCZ-spectrum disorders is usually seen in early adulthood from ages 14–30 years, with a peak age of 20.5 years and a median age of onset of 25 years (Solmi et al., 2023). The lifetime occurrence of SCZ is approximately 1%, while the employment rate among individuals with the disorder is poor, at only 10%–15% (Dixon, 2017). Individuals with schizophrenia commonly face a range of physical comorbidities (He et al., 2022), engage in unhealthy lifestyle choices (Firth et al., 2020), and display numerous risk factors for cardiovascular and other medical conditions (Rossom et al., 2022). The primary approach in current pharmacotherapy for the treatment of SCZ involves the use of antipsychotic (AP) drugs. However, these medications have limited effectiveness in addressing negative and disorganized symptoms. They are also ineffective in approximately 30% of the cases when it comes to treating psychosis and is associated with a noteworthy incidence of adverse effects such as drug-induced parkinsonism (e.g., haloperidol) or weight gain or predisposition to metabolic

conditions such as diabetes and hyperlipidemia (e.g., olanzapine; Pillinger et al., 2020).

The boundaries delineating SCZ from other psychiatric syndromes are overlapping. No single symptom is pathognomonic of SCZ; symptom overlaps are commonly observed with other psychotic and mood conditions, and childhood neurodevelopmental disorders (Lewine and Hart, 2020). The diagnosis of SCZ is based on the conceptualization of the disorder in the International Classification of Diseases (ICD) and Diagnostic Statistical Manual (DSM). These diagnostic guidelines are developed by the World Health Organization and American Psychiatric Association, respectively. To evaluate the patient, a thorough analysis of their background is conducted, including a detailed history and a mental status examination. It is crucial to assess the potential risks of self-harm or harm to others, as well as to consider the impact of substance use during this evaluation process. According to DSM-5-TR, the diagnostic criteria of SCZ comprise two or more presentations of delusions, hallucinations, disorganized speech and grossly disorganized or catatonic behavior, negative symptoms (i.e.,

<sup>1</sup>Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; <sup>2</sup>LSI Neurobiology Programme, National University of Singapore, Singapore;


<sup>3</sup>Healthy Longevity Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; <sup>4</sup>Quantitative Biosciences, MSD International GmbH, Singapore Branch, Singapore; <sup>5</sup>North Region, Institute of Mental Health, Singapore; <sup>6</sup>Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; <sup>7</sup>Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A\*STAR), Singapore

\*Correspondence to: John Jia En Chua, PhD, phsjc@nus.edu.sg.  
<https://orcid.org/0000-0002-5615-1014> (John Jia En Chua)

**Funding:** This work was supported by the Ministry of Health National Medical Research Council (to JL) and the National University of Singapore (to JJE).

**How to cite this article:** Lim DXE, Yeo SY, Chia ZYA, Fernandis AZ, Lee J, Chua JJE (2026) Schizophrenia: Genetics, neurological mechanisms, and therapeutic approaches. *Neural Regen Res* 21(3):1089–1103.





**Figure 1 | Positive, negative, and cognitive symptoms of schizophrenia.**

Positive symptoms encompass a range of experiences, such as hallucinations, delusions, and disorganized thinking in speech and behaviors. Negative symptoms refer to a reduction or absence of normal emotional responses and behaviors, including avolition, anhedonia, asociality, blunted effect, and alogia. Cognitive deficits involve impairments in mental processes, such as divided attention, poor working memory, slow processing speed, problems learning new information, and impaired ability to interpret social cues. Created with BioRender.com.

diminished emotional expression or avolition) for a substantial period during a month. Similarly, ICD-10 states that a patient must portray at least one of the positive symptoms or at least two of the negative symptoms coupled with catatonic behavior for a period greater than or equal to a month (First, 2024). Contrasting to DSM-5-TR, ICD-10 classifies SCZ into different subtypes based on the prominent symptoms observed in the individuals. These subtypes include paranoid SCZ, hebephrenic SCZ, catatonic SCZ, undifferentiated SCZ, post-schizophrenic depression, residual SCZ, simple SCZ, SCZ, other, and SCZ, unspecified. Although the use of ICD and DSM has allowed the general diagnosis and treatment decisions, the frameworks limit the comprehensive study of the disorder (Deacon, 2013).

There is no diagnostic biomarker for SCZ. Hence, diagnosis of SCZ requires both subjective reports and behavioral observations since there is no existing exhibit of clinical and biological diversity (Butcher et al., 2020; Bakken, 2021). On top of that, there is currently inadequate progress in developing diagnostic schemes and treatments based on its underlying pathophysiology. Despite extensive studies, conclusive pathological alterations similar to the presence of senile plaques and neurofibrillary tangles observed in Alzheimer's disease have not been detected in the postmortem brains of SCZ patients. Understanding the pathogenesis underlying SCZ is crucial to making progress in developing diagnostic approaches that are rooted in the underlying pathology and developing therapeutic options (Zhuo et al., 2019; Kimura et al., 2021).

SCZ is highly heritable, with 60%–80% heritability based on twin studies (Föcking et al., 2019; Cheng et al., 2021). By utilizing a large-scale genome-wide association study (GWAS) and leveraging single nucleotide polymorphism-

based heritability estimates to dissect the genetic architecture of SCZ, significant genetic loci, and pathways associated with SCZ susceptibility have been identified, shedding light on the genetic underpinnings of the disorder (Trubetskoy et al., 2022). Therefore, by taking into account all detectable common genetic variants, even those with minimal or unsubstantial statistical correlation, researchers were able to elucidate over 20% of the susceptibility to SCZ (Nakamura and Takata, 2023). In this review, we will present recent clinical aspects of SCZ, summarize affected neurological pathways and mechanisms and specific genes involved, discuss leading therapeutics, and highlight upcoming drug targets in clinical trials.

## Search Strategy

A comprehensive literature review on schizophrenia was conducted by utilizing databases such as PubMed, EMBASE, PsycINFO, and Medline, employing a multifaceted search strategy. Keywords related to the condition (schizophrenia, psychosis), symptoms (delusions, hallucinations, cognitive deficits), clinical outcomes (hospital admission, functional outcomes), clinical progression (first episode psychosis), drug targets (dopamine receptors, glutamate receptors), treatment strategies (antipsychotic medications, psychosocial interventions, clinical trials, drug targets), neurotransmitter systems (dopaminergic, glutamatergic, serotonergic) using “OR” within each category and “AND” to link categories.

## Clinical Course, Trajectories, and Diagnosis of Schizophrenia

The majority of people with SCZ experience a prodromal period lasting several years, accompanied by notable psychosocial impact (Verdolini et al., 2022). The extent of both positive

and negative symptoms are crucial determinants of patients' clinical progression, where cognitive deficits and other non-clinical factors (e.g., family support and social stigma) may also play a role (Harvey and Strassnig, 2012; Galderisi et al., 2014; Galderisi et al., 2020).

### Positive symptoms

Awareness and concern about positive symptoms, also commonly referred to as psychosis, (delusions, hallucinations, and thought disorder) are presumably more distressing to the patient and often the reason they seek help. Psychotic experiences can vary in intensity and severity, occurring at different levels across a range. These symptoms usually occur during adolescence to early adulthood, between ages 18 to 25 years. In a short-term study performed on young patients with SCZ, positive symptoms were observed to be greatly reduced at discharge and remain stabilized (Arndt et al., 1995; de Winter et al., 2023). While there were some studies conducted on SCZ patients that reported persistent positive symptomatology (Maïza et al., 2011; Cobia et al., 2012), others reported progress during the study period (Gur et al., 1998; Reske et al., 2007). These contrasting results may have stemmed from the sample size used in the studies, where a smaller cohort of patients was used in studies that concluded persistent positive symptoms, and larger sample sizes were utilized in most of the studies that found favorable progress in symptom remission (Heilbronner et al., 2016).

Furthermore, long-term course studies that followed SCZ patients after 15 years found that while their negative symptoms remained stable, there was a significant decrease in paranoid and hallucinatory (positive) symptoms (Möller et al., 2010). Two separate studies assessed data from the Chicago Follow-up Study on the long-term course of positive symptoms with intervals of up to 20 years. The first study included patients with SCZ and bipolar disorder for the occurrence of Schneiderian first-rank symptoms, such as delusional perceptions and commenting voices found that 44% of patients with SCZ experienced these symptoms 2 and 4.5 years after their initial admission (Rosen et al., 2011). However, the prevalence decreased to 30% at the 10-year follow-up, only to increase again to 44% at the 20-year follow-up (Rosen et al., 2011). Another study examined hallucinations alone over time and found approximately 80% of patients with SCZ experienced these symptoms during their initial hospitalization (Goghari et al., 2013). This percentage consistently decreased to around 30% at the 15-year follow-up and demonstrated only a slight increase at the final measurement point of 20 years (Goghari et al., 2013). These studies make it challenging to draw definitive conclusions about the impact of medication status. However, it seems that a greater number of unmedicated individuals tend to experience longitudinally fluctuating positive symptoms.

### Negative symptoms

Negative symptoms of SCZ often manifest during the prodromal phase of the disorder, preceding the first acute psychotic episode (An der Heiden et al., 2016; Correll and Schooler, 2020). It was previously found that the majority (70%) of

individuals experiencing negative symptoms had them prior to the onset of positive symptoms, while 20% of them showed negative and positive symptoms concurrently within the same month (An der Heiden et al., 2016). Hence, the emergence of negative symptoms during the prodromal stage has been identified as a potential risk factor for the transition to psychosis and healthcare providers are urged to remain vigilant regarding the presence of positive symptoms accompanied by lack of emotional expression, extensive social isolation, and signs of cognitive dysfunction (Goff, 2021).

Moreover, negative symptoms are harder to diagnose and treat (Kirkpatrick et al., 2023). Indeed, up to 60% of patients suffering from prominent negative symptoms are left untreated (Correll and Schooler, 2020), denoting an area of critical unmet medical need. This in part stemmed from the emphasis on positive symptoms and the notion that improvements in positive symptoms will extend beneficially to negative symptoms. Additionally, the clinical overlap between cognitive function and negative symptoms might lead clinicians to prioritize treatment for the former (Kirkpatrick et al., 2006; Skiba et al., 2024). To circumvent these issues, progress in developing valid scales for assessing and identification of negative symptoms has been made, even as efforts are still being made to develop interventions (Galderisi et al., 2021). Negative symptoms can be further categorized into primary (directly associated with SCZ) or secondary. The latter can be caused by positive symptoms, depression, extrapyramidal side effects of AP drug therapy, or other contributing factors such as substance abuse. As per the recommendations provided by the European Psychiatry Association regarding the management of negative symptoms, various interventions have demonstrated positive effects on alleviating these symptoms. These interventions include the use of second-generation AP drugs (i.e., risperidone, cariprazine, and olanzapine), antidepressant medications, psychosocial rehabilitation programs (such as social skills training), cognitive remediation techniques, and incorporating exercise into the treatment regimen (Galderisi et al., 2021). Nonetheless, the psychopathologic mechanisms driving negative symptoms remain poorly understood compared to those underpinning positive symptoms, which are more comprehensively studied (Habtewold et al., 2023; Wang et al., 2023).

In a study conducted to track long-term trajectories of first episode psychosis to investigate symptom course based on longitudinal clinical data, it was reported that the majority of participants in the study experienced a decrease in positive symptoms that eventually stabilized over time (Starzer et al., 2023). Furthermore, changes in negative symptoms were less pronounced, with more than half of the participants showing minimal or no significant changes from their initial levels (Starzer et al., 2023). The findings of this study align with the existing research on negative symptoms where patients with these symptoms are likely to experience them throughout the illness course (Butcher et al., 2020; Okada et al., 2021) and remain unresponsive to current treatments (Remington et al., 2015a; Mosolov

and Yaltonskaya, 2021). Additionally, the extent of these symptoms has a direct impact on overall long-term functioning and recovery rates (Kalisova et al., 2023). These results suggest that compared to positive symptoms, negative symptoms result in a more persistent, deteriorating ramification of illness progression in SCZ patients.

### Cognitive impairment

Cognitive impairment is a fundamental characteristic of SCZ that persists throughout the illness. Nevertheless, due to the challenges associated with investigating cognitive decline in individuals before the onset of the illness, the long-term trajectory is not completely comprehended. The period onset of cognitive impairment remains tricky to determine, and much of whether these intellectual inabilities predate psychosis as well as the degree of decline throughout the illness course remain unclear.

Impairment in cognitive function typically commences during adolescence in individuals who subsequently develop SCZ (MacCabe et al., 2013; Sakurai and Gamo, 2019). The current available evidence regarding the advancement of impairments after the onset of illness shows varying levels of consistency. There is a clear indication of a decline in cognitive function from the period prior to the onset of psychotic symptoms to the period following it (Karr et al., 2018; Sheffield et al., 2018). Although cognitive deficits often accompany psychosis, AP drugs do not effectively address or improve these cognitive impairments (Nielsen et al., 2015; McCleery and Nuechterlein, 2019). In fact, AP drugs show limited effectiveness in enhancing daily functioning, and studies indicate that functional impairment is more strongly linked to cognitive deficits rather than the severity of psychotic symptoms (Velligan et al., 1997; Harvey et al., 2022). As a result, addressing cognitive deficits becomes a crucial focus for enhancing the well-being of individuals living with psychotic disorders such as SCZ.

A cognitive function study performed two years after patients who exhibited the first episode psychosis observed improvement in verbal learning, and other aspects of cognitive functioning remained stable (Amoretti et al., 2021). Tapping onto the Chicago Follow-up Study, a group studied a subsample of the cohort and discovered that SCZ patients demonstrated declining performance over time in a test of executive function, specifically verbal fluency, while maintaining stable performance in most other cognitive domains (Burdick et al., 2006; Harrow et al., 2017). In short, SCZ sufferers commonly display significant deficits in overall cognitive function, usually averaging around two standard deviations below that of individuals without the condition (Keefe et al., 2011; McCutcheon et al., 2023).


Overall, late-onset SCZ patients may portray signs of dementia based on a five-year follow-up study where almost half of the patients met the criteria for dementia (Brodaty et al., 2003; Yang et al., 2023), identifying potential neurodegenerative changes in SCZ that develops later in life or suggesting the presence of concurrent dementia. The decline in cognitive function may be a common characteristic of SCZ in older individuals as they tend to experience a gradual decline

in cognitive function as indicated by the Mini-Mental State Examination (Friedman et al., 2001). However, most studies do not provide enough details about the medication status of the participants to make any definitive conclusions about the impact of psychopharmacology on the collected results.

There is substantial evidence suggesting a decline in cognitive function prior to the emergence of psychotic symptoms, continuing into the period that follows. A recent study of the genetics underlying treatment-resistance SCZ (TRS) uncovered genes related to glutamatergic synaptic transmission and regulation embedded in the TRS genetic signal (Lim et al., 2023). This suggests the involvement of neurodevelopmental pathways in the development or risk predisposition to TRS. However, pinpointing the exact timing of this onset remains challenging. Conversely, a significant majority of patients as previously discussed report experiencing negative symptoms before the appearance of positive symptoms. **Figure 2** illustrates the variability in drug responses to AP drugs among patients and can be categorized into three distinct categories (antipsychotic responsive, primary TRS, and secondary TRS). Notably, the antipsychotic responsive group consists of patients who respond favorably to AP medications, achieving a reduction in positive symptoms that falls below the diagnostic threshold (**Figure 2A**), primary TRS patients show no response to AP drugs from the outset and continue to exhibit a lack of improvement even after two treatment trials (**Figure 2B**), and secondary TRS patients may initially respond well to the first administration of AP drugs but later develop resistance to the drugs over time (**Figure 2C**).

### Current treatment practices and their limitations

The treatment of SCZ has evolved. First-generation antipsychotics (FGAs), such as chlorpromazine and haloperidol, were the mainstay of treatment for several years. However, since the 1990s, the introduction of second-generation antipsychotics (SGAs) has led to changes in the approach to treatment. These newer medications, also known as atypical antipsychotics, have become more commonly prescribed due to their potentially reduced side effects. 10 years later, conclusions from a comprehensive analysis, including a systematic review and meta-regression of 52 randomized controlled trials involving 12,649 patients comparing the effects of FGAs with SGAs, suggested that the initial perspective of SGAs having marginally better effectiveness, improved tolerability, and a decreased likelihood of causing extrapyramidal symptoms was overly simplistic (Geddes et al., 2000). In comparison to a specific group of patients who were administered 12 mg/day or less of haloperidol (or its equivalent), they observed that there was no distinction in efficacy or overall tolerability between FGAs and SGAs. Moreover, they found that SGAs were only marginally better at causing fewer extrapyramidal symptoms (Geddes et al., 2000; Zhang et al., 2013). Despite this, it is acknowledged that numerous patients with chronic illnesses continue to display an inadequate response to both FGAs and SGAs (AP drugs) treatment, categorized broadly as treatment resistance SCZ (TRS) (Buckley, 2020).



**Figure 2 | Treatment response to AP drugs by different groups of patients.**

There is a clear indication of a decline in cognitive function prior to the onset of psychotic symptoms to the period following it, albeit the period of onset is difficult to determine. Most patients (~70%) experience negative symptoms prior to the onset of positive symptoms. Current drug treatments are mainly focused on treating the positive symptoms of SCZ. As a result, negative symptoms and cognitive deficits are often left untreated. However, there are differences in response to AP drugs as well, which can be categorized into three categories. (A) Antipsychotic responsive is the group of patients that responds well to AP drug, showing a reduction in positive symptoms to below the diagnostic threshold. (B) Primary TRS is the group of patients that do not show any response to AP drugs right from the very start and exhibit a lack of response even after two trials of AP drugs. (C) Secondary TRS is the group of patients that initially had good responses to the initial AP drug administration but exhibited resistance to the AP drug after a period. Created with BioRender.com. AP: Antipsychotic; SCZ: schizophrenia; TRS: treatment-resistant schizophrenia.

TRS occurs in 30%–40% of patients and remains a major clinical challenge (Meltzer et al., 1997; Lally et al., 2016; Demjaha et al., 2017). The exact cause for the ineffectiveness is currently unknown although studies have shown contributory causes from both genetics and environmental factors (Takeuchi et al., 2019; Zoghbi et al., 2021; Lim et al., 2023). Based on the definition by the Treatment Response and Resistance in Psychosis (TRIP) Working Group, TRS is often defined by the lack of response after two trials of AP drugs prescribed for a substantial amount of duration, dose, and usage compliance. Initial resistance to treatment with AP drugs is observed at the inception of therapy (primary TRS), whereas a group of patients may exhibit resistance to the medication only after a period of treatment (secondary/late onset), frequently following relapses (Correll and Howes, 2021). Primary TRS is associated with neurodevelopmental origins and patients generally show greater severity in symptoms (Demjaha et al., 2017). Patients with secondary TRS may suffer from more relapses or have prior interruptions in their antipsychotic treatment, i.e. non-adherence or treatment discontinuation (Emsley et al., 2012; Takeuchi et al., 2019) or other comorbidities.

At present, there exists a knowledge gap with regard to primary and secondary TRS. It remains unclear how to identify them, whether early intervention is effective, if early use of clozapine is significant, or if there exists a distinct neurobiological subtype for which we lack treatment options. The development of SGAs

is also geared toward long-acting injectables to minimize nonadherence, management of the disease and outcomes (Brasso et al., 2023; Fernandez-Miranda et al., 2024). However, while medication adherence plays a role in treatment response, there may also be elements of AP drug tolerance and dopamine super-sensitivity – where prolonged treatment with AP can lead to an upregulation of dopamine receptors in the brain, which may result in increased dopamine activity when the medication is withdrawn or reduced (Chouinard et al., 2017). Even with the introduction of SGAs, up to 60% of patients with TRS may not respond positively to clozapine, underscoring the pressing requirement for the development of therapeutics utilizing novel mechanisms of action (Potkin et al., 2020).

## Neurotransmitter Systems Driving Positive, Negative, and Cognitive Symptoms


SCZ is a multifaceted psychiatric disorder characterized by cognitive deficits, hallucinations, and delusions, with key neurobiological involvement from the prefrontal cortex, midbrain, and hippocampus (Figure 3). The interplay between various neurotransmitter pathways, dopaminergic, glutamatergic, serotonergic, and GABAergic, is central to understanding the complex pathophysiology of SCZ. Research indicates that these systems do not operate in isolation. Rather, they interact in ways that significantly influence the symptoms and development of the disorder.

In the prefrontal cortex, dysregulation of glutamatergic, serotonergic, and muscarinic signaling pathways through glutamate, GABA, and acetylcholine contributes to impaired cognitive functions such as decision-making and memory. Glutamatergic pyramidal neuron communicates with medium spiny neurons in the nucleus accumbens and dopaminergic neurons in the midbrain through the flow of glutamate and dopamine. There is extensive evidence suggesting that dysregulation in dopamine transmission is closely linked to alterations in glutamatergic signaling. For example, N-methyl-D-aspartate (NMDA) receptor hypofunction (a glutamatergic pathway) is thought to lead to increased dopaminergic activity, particularly in the mesolimbic pathway, which correlates with positive symptoms of SCZ. Conversely, insufficient activation of dopaminergic transmission in the prefrontal cortex can contribute to cognitive and negative symptoms (Deng and Dean, 2013; Buck et al., 2022). GABAergic neurons play a crucial role in modulating excitatory glutamatergic signaling. In SCZ, reduced GABA synthesis has been observed, which can lead to increased glutamate levels and further exacerbate excitatory transmission. This imbalance may contribute to the hyperactivity of dopaminergic pathways, leading to psychotic symptoms (Buck et al., 2022).

Moreover, the interaction between serotonin and dopamine systems is considered a viable mechanism for enhancing therapeutics in SCZ (De Deurwaerdere et al., 2021). Serotonin-dopamine activity modulators may improve negative symptoms by helping to control the activity of serotonin and dopamine (Brasso et al., 2023). The serotonin system inhibits dopaminergic function in the midbrain and forebrain, and serotonergic antagonists release the dopamine system from this inhibition (Courtillot et al., 2021). This disinhibition may alleviate neuroleptic-induced extrapyramidal symptoms and ameliorate negative symptoms (Courtillot et al., 2021). However, combined serotonergic-dopaminergic blockade benefits may be observed in a narrow dose range and lost with suprathreshold dopaminergic blockade. Current research is exploring the possibility of using specific serotonergic treatments as flexible adjuncts to typical neuroleptics. Beyond dopamine, increasing evidence implicates serotonin and glutamate networks in the pathophysiology and treatment of some forms of psychosis (Stahl, 2018). Besides the prefrontal cortex, the muscarinic pathway in the hippocampus is also implicated, where cholinergic neurons send signals to CA1 pyramidal neurons through acetylcholine (Figure 3). We discuss the different signaling pathways in greater detail in the next section.

### Dopamine pathways

It is hypothesized that patients with SCZ who respond to treatment and those who are resistant to treatment represent distinct subtypes (Demjaha et al., 2014). Additionally, the neurobiology of patients who initially respond to therapy but later develop resistance during the treatment course is also distinct (Takeuchi et al., 2019). The dopamine hypothesis posits that an imbalance in dopaminergic neurotransmission contributes to the positive symptoms of SCZ. Specifically, excessive dopamine activity in certain brain



**Figure 3 | Overview of neurotransmitter systems implicated in schizophrenia.**

Schizophrenia is associated with dysfunction in specific brain regions, notably the prefrontal cortex, midbrain, and hippocampus. Within the prefrontal cortex, several neurotransmitter signaling pathways, including glutamatergic, serotonergic, and muscarinic systems, are involved. Disruption in any of these pathways may contribute to the pathophysiology of schizophrenia. The muscarinic signaling pathway also plays a significant role in the hippocampus, where cholinergic neurons interact with CA1 pyramidal neurons through the neurotransmitter acetylcholine. In the midbrain, dopaminergic neurons communicate with medium spiny neurons in the nucleus accumbens, primarily through the release of dopamine. These interactions highlight the complex neurochemical landscape that underlies schizophrenia and its associated cognitive deficits. Created with BioRender.com. GABA: Gamma aminobutyric acid.

regions, such as the mesolimbic pathway, is linked to the development of positive symptoms (Figure 4, see the section Dopaminergic Pathway, Midbrain and Nucleus Accumbens). AP drugs, which primarily target dopamine D2 receptors, effectively reduce these symptoms, providing clinical support for this hypothesis (Howes and Kapur, 2009; Boyd and Mailman, 2012). In contrast, positron emission tomography studies have reported unchanged or decreased dopamine levels in TRS (Demjaha et al., 2017; Jauhar et al., 2019; Takeuchi et al., 2019). Additionally, patients unresponsive to clozapine exhibit decreased dopamine synthesis in the striatum (Kim et al., 2017). These findings suggest that the mechanisms underlying TRS are distinct from those in treatment-responsive patients and may also vary within the spectrum of treatment-resistant cases. Moreover, while dopamine dysregulation evidently plays a role in the symptoms of SCZ for many patients, the inability of AP dopamine blockers to manage symptoms in some cases suggests that other neurotransmitters are likely involved in the development of TRS (Schwartz et al., 2012; Brisch et al., 2014). Early detection and appropriate intervention in TRS hold promise in improving outcomes. Therefore, identification of individuals who might be TRS, or not responsive to antipsychotics that target


dopamine pathways in particular, is an important clinical strategy in precision psychiatry.

#### Glutamatergic pathways

Negative and cognitive symptoms of SCZ are thought to be associated with dysfunctional glutamatergic neurotransmission (Stogios et al., 2021; Mecca et al., 2022). Glutamate, the primary excitatory neurotransmitter in the brain, plays a crucial role in synaptic plasticity and cognitive processes. Disturbances in glutamate signaling, particularly in the NMDA receptor system, have been implicated in the pathogenesis of these symptoms (Pal, 2021). The glutamate hypothesis has been proposed to elucidate the role of alternative neurotransmitter systems in the neurobiology of SCZ. It suggests that dopaminergic hyperactivity is a downstream effect of disruptions in glutamate and gamma aminobutyric acid (GABA) signaling (Howes et al., 2015). NMDA receptor (NMDAR) hypofunction on GABAergic interneurons serves as the initial perturbation, and its dysfunction results in a diminished inhibitory control exerted by GABAergic interneurons on glutamatergic pyramidal neurons in cortical and hippocampal regions (Nakazawa and Sapkota, 2020). Consequently, there is a disinhibition of these glutamatergic neurons,

particularly those projecting to the basal ganglia, leading to their hyperactivation and excessive glutamatergic signaling, which in turn modulate the dopaminergic transmission in the mesolimbic pathway (Lodge and Grace, 2007; Lodge et al., 2009; Schwartz et al., 2012). Evidence supporting this hypothesis comes from pharmacological studies involving phencyclidine, a known NMDA receptor antagonist. Clinical observations demonstrate that individuals with SCZ experience an intensification of positive symptoms when administered phencyclidine. Furthermore, when healthy subjects were prescribed phencyclidine, they exhibited symptoms that closely resembled the positive symptoms characteristic of SCZ (Fujigaki et al., 2019). These findings lend credence to the proposed role of NMDA receptor dysfunction in the pathophysiology of SCZ (Figure 4, see the section Glutamatergic Pathway, Prefrontal Cortex).

Neuroimaging studies have revealed elevated glutamate levels in the anterior cingulate cortex of TRS patients compared to both healthy controls and treatment-responsive patients, suggesting that disruptions in glutamatergic signaling may play a role in TRS (Demjaha et al., 2014, 2017; Mouchlianitis et al., 2016). Studies of clozapine



**Figure 4 | Proposed pathological pathways of schizophrenia.**

(A) Dopamine hypothesis begins in the midbrain, where the dopaminergic neurons produce and release much more dopamine than usual, which can affect the mesolimbic pathway as it excites the medium spiny neurons in the nucleus accumbens that governs the reward system in the brain. Glutamate hypothesis suggests that in the prefrontal cortex, hypofunction of the NMDA receptor at the GABAergic interneurons results in fewer GABA inhibitory signals to the glutamatergic pyramidal neuron. This, in turn, causes the glutamatergic neuron to release more excitatory glutamate neurotransmitters to the midbrain and nucleus accumbens. (B) Serotonin hypothesis is less well defined, but it has been shown that imbalances in 5HT receptors, particularly subtypes 1 and 2, are associated with increased dopamine levels in the striatum. (C) Muscarinic hypothesis is based on the evidence that muscarinic receptors, particularly M1R (blue), have lowered expression in the brain, particularly the cortical and hippocampal regions. In the hippocampus, M1R is suggested to inhibit Kv7 to depolarise the CA1 pyramidal neuron, as well as increase NMDA receptor activity by inhibiting the SK potassium ion channel. The overall effect is the increased excitability of the CA1 pyramidal neurons while promoting long-term potentiation and synaptic plasticity. In schizophrenic patients, the reduced level of M1R in the hippocampus would result in the fall in long-term potentiation and synaptic plasticity in the hippocampus, which is associated with a decrease in learning and cognitive function. Reduced level of M1R in the cortical region is also shown to reduce long-term depression of glutamate signaling by the pyramidal neurons and is associated with an increase in dopamine levels in the striatum. On cholinergic interneurons, M4R (red) regulates dopamine release by inhibiting excessive release of acetylcholine, thereby preventing excessive nAChR-dependent release of dopamine in dopaminergic neurons. In D1-spiny projection neurons, it is shown that M4R activation stimulates the release of 2-AG, which inhibits dopamine release via a cannabinoid receptor-dependent pathway. Decreased levels of M4R result in the disinhibition of dopamine release, resulting in increased levels of dopamine in the striatum. Created with BioRender.com. 2-AG: 2-Arachidonoylglycerol; GABA: gamma aminobutyric acid; LTP: long-term potentiation; NMDA: N-methyl-D-aspartate; NMDAR: N-methyl-D-aspartate receptor.

on the glutamatergic system serve to provide indirect evidence for the neurotransmitter role in clozapine-responsive TRS (Tanahashi et al., 2012). In a rat model, it has been shown that clozapine exhibits a strong affinity for DRD4 receptors. Blockade of DRD4 receptors in this model resulted in an upregulation of  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, thereby enhancing glutamatergic transmission (Yuen et al., 2010; Veerman et al., 2014). Similarly, clozapine enhances the release of L-glutamate and D-serine and has the potential to upregulate NMDA receptors as a result (Tanahashi et al., 2012). It is also proposed that clozapine can compensate for the hypofunctional state of NMDA receptors in some TRS patients (Veerman et al., 2014). In a study that investigated the levels of D- and L-serine in patients with TRS before and after clozapine treatment, it was found that patients with TRS had significantly lower D-serine levels compared to healthy controls prior to receiving clozapine treatment. However, this difference in

D-serine levels between patients with TRS and healthy controls became non-significant after the administration of clozapine treatment (Yamamori et al., 2014). Likewise, the study also revealed that the D-/L-serine ratio was notably lower in patients with TRS prior to receiving clozapine treatment. However, after the administration of clozapine, the D-/L-serine ratio in patients with TRS was not significantly different from that of healthy controls. This finding further strengthens the hypothesis that the mechanism of action of clozapine may involve the regulation of a dysfunctional glutamatergic pathway in individuals with TRS (Yamamori et al., 2014).

#### Serotonin and GABAergic pathways

Other neurotransmitter systems, such as serotonin and GABA, are also believed to be involved in the pathophysiology of SCZ and may contribute to negative and cognitive symptoms. Most studies have focused on serotonin as one of the biomarkers for cognition. It is also known as 5-HT

(5-hydroxytryptamine), acts as a neurotransmitter that regulates many consequential physiological processes such as sleep, motor activities, and higher brain functions, including cognition and emotional behaviors (Ciranna, 2006). Preclinical and clinical studies have shown that the 5-HTergic system activity is related to cognitive performance in many psychiatric disorders including SCZ (Lin et al., 2014). Moreover, altered serotonergic and GABAergic neurotransmission at the prefrontal cortex may disrupt neural circuitry and synaptic function (Dean, 2001; Boyer et al., 2007), leading to impairments in emotional regulation, attention, and information processing (Figure 4B).

There is abundant evidence showing that the 5-HT system plays a major role in regulating the activity of dopamine in the brain, and *vice versa* (Akhondzadeh, 2001; Brisch et al., 2014). 5-HT1A and 5-HT2A receptors are given more attention as they are attributed to the development and progression of SCZ. These two receptors are often found together on the same cell, even though

they are known to trigger opposing responses. During the early stages of abnormalities in the SCZ brain, it is often found that there is an imbalance of 5-HT1A (higher) and 5-HT2A (lower) receptors (Ngan et al., 2000; Hurlmann et al., 2008). This downregulation of 5HT2A could be a form of compensatory mechanism for hyperactive downstream signaling in which 5-HT2A receptors are known to regulate the ERK pathway which is proposed to upregulate NMDAR function on prefrontal cortex pyramidal neurons (Yuen et al., 2008). This could explain how serotonin is linked to psychosis and why 5-HT2A antagonists are often used as atypical antipsychotic drugs (**Figure 4**, see the section Serotonin Hypothesis). Moreover, irregular ratios in receptor density are closely linked to the severity of positive and negative symptoms, which are commonly evaluated using the Scale for the Assessment of Negative Symptoms and the Scale for the Assessment of Positive Symptoms.

Similarly, GABAergic dysfunction has been implicated in cognitive impairments in TRS patients in particular (Miyazawa et al., 2022). In the study, exome sequencing conducted on 14 TRS patients identified four single nucleotide polymorphisms with GAD1 and GABBR2 showing nominal-level significance when compared against healthy controls, suggesting that the GABA system is compromised in SCZ or TRS (Miyazawa et al., 2022). Other supportive studies conducted previously concurrently reported the decreased levels of GAD67 mRNA in SCZ patients, further supporting the importance of the GABAergic system (Raux et al., 2007; Vorstman et al., 2009). Furthermore, the GABA system is a target for clozapine where the drug is thought to directly bind to GABAB receptor (Gammon et al., 2021). A recent study conducted on 98 treatment-responsive and resistant SCZ patients also revealed the overall group differences in the GABA levels of the midcingulate cortex using proton magnetic resonance spectroscopy (Ueno et al., 2022). Heightened levels of GABA are reported in resistant SCZ patients with more longitudinal studies required to determine if GABA levels could be a potential biomarker for clozapine resistance prediction (Ueno et al., 2022).

### Muscarinic pathways

Muscarinic receptors are a class of receptors that respond to the neurotransmitter acetylcholine. These receptors play a significant role in various physiological processes, including cognition, memory, attention, and sensory perception. The cholinergic hypothesis of SCZ proposes that dysfunction in the muscarinic receptor system may contribute to the cognitive impairments observed in the disorder.

Studies have shown that there were alterations in muscarinic receptor density and function in individuals with SCZ, particularly in brain regions involved in cognitive processes. Specifically, decreased levels of muscarinic receptors, particularly the M1 subtype, have been reported in the prefrontal cortex and hippocampus of individuals with SCZ (Dean et al., 2023). These brain regions are critical for working memory, attention, and executive functions that are commonly impaired in SCZ.

Studies in rodent models provided insight into how the M1 receptor (M1R) contributes to the pathology of SCZ. In particular, M1R localized in the hippocampal region is critical in the learning and memory processes by modulating synaptic plasticity (Dickinson et al., 2009; Bradley et al., 2010; Buchanan et al., 2010; Dasari and Gullledge, 2011) and promoting long-term potentiation (Adams et al., 2004; Langmead et al., 2008; Buchanan et al., 2010; Dasari and Gullledge, 2011; Mitsushima et al., 2013). It is suggested that activation of M1R leads to increased CA1 pyramidal neuron excitability via two ways; the inhibition of voltage-dependent Kv7 potassium channel that generates M currents, which are antagonistic to neuronal depolarization (Hoshi, 2020), and the inhibition of SK potassium channels, which negatively regulates potentiation of NMDARs (Buchanan et al., 2010). Low M1R expression in schizophrenic patients would therefore have lower CA1 pyramidal neuronal excitability, and hence reduced long-term potentiation and synaptic plasticity in the hippocampal region, affecting cognition (**Figure 4**, see the section “Muscarinic Pathway, Hippocampus”). Reduced expression of M1R on GABAergic interneurons in the cortical region also leads to fewer release of GABA neurotransmitters onto the glutamatergic pyramidal neurons, resulting in increased excitability and subsequently in increased release of glutamate neurotransmitters onto the dopaminergic neurons in the midbrain (Paul et al., 2022; **Figure 4**, see the section “Glutamatergic Pathway, Prefrontal Cortex”). A complete knockout of M1R in mice also revealed that M1R plays a role in activating the mitogen-activated protein kinase (MAPK) pathway, which has a large impact on synaptic plasticity and cognitive ability (Hamilton and Nathanson, 2001; Adams and Sweatt, 2002). M1R deficient mice were also found to be associated with a two-fold increase in dopamine levels in the striatum (Gerber et al., 2001).

M4R, mainly localized in the striatum of the brain, is also found to be linked to the pathophysiology of SCZ. M4R expressed on both cholinergic interneurons and D1-spiny projection neurons were reported to play a role in regulating dopamine release (Shin et al., 2015). On cholinergic interneurons, M4R is expressed as an autoreceptor, and is suggested to regulate dopamine release by inhibiting excessive release of ACh, thereby preventing excessive nAChR-dependent release of dopamine in dopaminergic neurons (Shin et al., 2015). In D1-spiny projection neurons, it is shown that M4R activation stimulates the release of 2-arachidonoylglycerol (2-AG), which inhibits dopamine release via a cannabinoid receptor-dependent pathway (Foster et al., 2016). Decreased levels of M4R result in the disinhibition of dopamine release, resulting in increased levels of dopamine in the striatum (**Figure 4**, see the section Muscarinic Pathway, Striatum).

Animal studies using M4 loss of function (CHRM4<sup>-/-</sup>) mice support the receptor-critical roles in regulating both dopaminergic and cholinergic activity in the sub-cortical regions (Gomez et al., 1999; Tzavara et al., 2004). Mice lacking the CHRM4 gene have notably higher baseline levels of dopamine in the nucleus accumbens. When exposed to d-amphetamine and phencyclidine,

these mice experience a more pronounced increase in dopamine release compared to normal mice (Tzavara et al., 2004). Moreover, there was a slight yet noteworthy rise in baseline locomotor activity, recognized as a behavior in mice linked to heightened dopaminergic function in the CHRM4<sup>-/-</sup> mouse (Gomez et al., 1999). These data substantiate the idea that the lack of CHRM4 leads to heightened dopaminergic activity in the central nervous system, which is also suggested to be implicated in the development of psychotic symptoms in individuals with SCZ (Dean et al., 2023). Hence, there exists a biological foundation for the proposition that selectively activating CHRM4 could serve as a mechanism to alleviate the psychotic symptoms of SCZ. This hypothesis has gained support from a recent trial indicating that the CHRM4 positive allosteric modulator, emraclidine, diminishes the severity of both acute psychotic and acute negative symptoms in individuals with SCZ. This provides evidence that targeting CHRM4 with emraclidine may be a promising approach for managing symptoms of SCZ (Krystal et al., 2022).

Moreover, findings using the CHRM4<sup>-/-</sup> mouse have also underscored the robust interactions of CHRM4 and the glutamatergic systems. This is evident as these mice exhibited heightened sensitivity to the disruption of pre-pulse inhibition following NMDAR blockade by phencyclidine (Felder et al., 2001). These data hold significance as abnormal control of pre-pulse inhibition has been proposed as a potential biomarker for the diagnosis of SCZ (Mena et al., 2016).

Additionally, manipulating the muscarinic receptor system through pharmacological interventions has shown potential for improving positive and negative symptoms, as well as cognitive impairments in SCZ. Lately, two successful Phase 3 (EMERGENT-2 and EMERGENT-3) trials of drugs targeting M1 and M4 receptors without dopamine D2 blockage to treat SCZ have been reported (Kaul et al., 2024b). Since the mechanisms by which muscarinic receptor dysfunction contributes to SCZ and the specific role of each muscarinic receptor subtype are still not fully understood, these promising data of novel drug inventions targeting muscarinic receptors for the treatment of SCZ reemphasizes the need to review the roles of these receptors in the disorder pathology (Dean et al., 2023). Overall, while alterations in muscarinic receptors and cholinergic neurotransmission have been implicated in the cognitive impairments seen in SCZ, more research is required to better understand the underlying mechanisms and develop targeted therapeutic approaches to address these deficits.

## Genes Implicated in Schizophrenia Identified by Recent Genome-Wide Association Study and Their Associated Molecular Pathways

### Genes involved in synaptic transmission

A recent study utilized MAGMA (de Leeuw et al., 2015) and DNENRICH (Fromer et al., 2014) to conduct gene ontology (GO) enrichment analyses in both the Psychiatric Genomics Consortium

GWAS and the Schizophrenia Exome Sequencing Meta-Analysis studies to test whether specific molecular and biological pathways were enriched among the associated genes (Nakamura and Takata, 2023). The study aims to uncover how the results from these two studies converged and identified enriched pathways, particularly in terms of molecular functions. Their result suggests that there is a convergence of molecular and biological pathways affected by both common single nucleotide polymorphisms and rare deleterious variants (Nakamura and Takata, 2023). Specifically, four GO terms related to voltage-gated channels and synaptic transmission were found to be significantly enriched in both the Psychiatric Genomics Consortium GWAS and the Schizophrenia Exome Sequencing Meta-Analysis studies, even after applying the Bonferroni correction. These findings indicate a possible involvement of these pathways in the genetic basis of the SCZ (Nakamura and Takata, 2023). Additionally, when the 32 GO terms with Bonferroni-corrected  $P < 0.05$  in either dataset were visualized as networks by connecting them based on the similarity of the contained genes, it was observed that there was a formation of three clusters, each related to channel or transporter activities; neuronal components (synapse, axon, and dendrite); chromatin or histone organization (Nakamura and Takata, 2023).

Several studies collectively provide evidence suggesting the involvement of voltage-gated calcium channels (VGCC) subunits in the pathogenesis of SCZ. Through linkage analyses, GWAS and candidate gene association studies, genes identified include *CACNA1C* (Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium, 2011; Ripke et al., 2013; He et al., 2014; Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014), *CACNB2* (Wang et al., 2010; Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013), *CACNG5* (Curtis et al., 2011; Guan et al., 2016) and *CACNA11* (Irish Schizophrenia Genomics Consortium and the Wellcome Trust Case Control Consortium 2, 2012; Andrade et al., 2016), encoding various subunits of the VGCC. The results suggest a potential involvement of VGCCs in the development of SCZ, although the exact molecular mechanism underlying this association is not yet understood.

Recent evidence also recasts the spotlight on the involvement of abnormalities in synaptic transmission and synaptic plasticity in SCZ (Stephan et al., 2009). The largest GWAS to date reported by Trubetskoy and coworkers identified a significant number of loci associated with synaptic genes in SCZ patients (Trubetskoy et al., 2022). Four of these genes (*GRIN2A*, *SP4*, *STAG1*, and *FAM120A*) were also listed amongst the 10 exome-wide significant Schizophrenia Exome Sequencing Meta-Analysis genes (Singh et al., 2022). Noteworthy, *GRIN2A*, which encodes the NMDAR subunit GluN2A, mediates excitatory synaptic transmission together with  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA) and kainate receptors. These receptors can be regulated by various neurotransmitter systems (Traynelis et al., 2010). NMDARs are remarkable because they serve a dual function as regulators

of both synaptic communication and long-term changes in synaptic strength, such as long-term potentiation and depression (long-term potentiation and long-term depression) of AMPAR-mediated synaptic signaling (Rebola et al., 2010; Hunt and Castillo, 2012). SCZ patients are known to demonstrate impaired NMDAR functions, along with an exacerbation of symptoms when exposed to NMDAR antagonists based on clinical studies (Law and Deakin, 2001; Weickert et al., 2013). In a validation study examining *GRIN2A* and *AKAP11*, it was found that *Grin2a* and *Akap11* mutant mice display patterns of brain activity that closely resemble the abnormal features observed in individuals with SCZ (Herzog et al., 2023). This suggests that the absence of these genes causes significant alterations in brain function, further supporting the characterization of these two genes as genetic models of SCZ (Herzog et al., 2023). *SP4*, on the other hand, is a transcription factor that regulates the expression of multiple target genes involved in neural development, synaptic function, and glutamate signaling (Priya et al., 2013). Mice with reduced expression of *SP4* exhibited multiple potential markers for SCZ and other psychiatric disorders (Zhou et al., 2010).

Additional analyses of the 106 prioritized genes using the SynGO database further shortlisted 48 genes with known synaptic localization or function, including genes encoding receptors and ion channels (voltage-gated calcium and chloride channels (*CACNA1C* and *CLCN3*), metabotropic receptors (glutamate (*GRM1*) and GABA (*GABBR2*)), and the afore-mentioned ligand-gated NMDAR subunit (*GRIN2A*) (Trubetskoy et al., 2022). *SNAP91* (Synaptosomal-associated protein 91) is a gene involved in endocytosis, a process that regulates the retrieval of neurotransmitter receptors from the cell surface back into the presynaptic terminal. *DLGAP2*, *LRR44B*, *GPM6A*, *PAK6*, and *PTPRD* are genes associated with synaptic organization and differentiation (Trubetskoy et al., 2022). These genes may play a role in the formation and maintenance of connections between neurons, and in the development of neuronal networks.

Other identified genes associated with synaptic function, *MAPK3*, *DCC*, *CLCN3*, and *DLGAP2*, were also prioritized in the study (Trubetskoy et al., 2022). They are thought to regulate the release and reception of neurotransmitters, which are crucial for neuronal communication. These findings suggest that abnormalities in endocytosis, synaptic organization, differentiation, and chemical transmission may contribute to the underlying molecular mechanisms of SCZ. Their findings further support other GWAS studies that propose abnormalities in the postsynaptic region of synapses playing a role in the SCZ pathogenesis. However, GWAS findings comprising the TRS subgroup that links to VGCC and synaptic biology are currently lacking.

#### Genes involved in immune and inflammatory pathways

SCZ is influenced by a range of genetic and environmental factors that elevate the risk of developing the disorder. Recent research suggests that these factors may converge through their effects on immune processes. Evidence indicates

that immune processes are critical in shaping brain development, as studies of SCZ patients have reported heightened immune function and increased chemokine responses (Frydecka et al., 2018; Kroken et al., 2018). Moreover, anti-inflammatory therapeutics targeting immune function have shown some efficacy in symptom remission (Sommer et al., 2014). Importantly, there is a correlation between subclinical inflammation and cognitive deficits in SCZ (Misiak et al., 2018), which usually determine illness prognosis.

Microglia, which are phagocytes within the central nervous system, have several roles including coordinating innate immunity in the brain. They have established functions in promptly responding to inflammatory stimuli by actively monitoring the central nervous system parenchyma (Liu et al., 2019), and contribute to the removal of debris and apoptotic cells through the process of phagocytosis (Ayata et al., 2018; Galloway et al., 2019). These highly complex cells also contribute to the integrity of neuronal circuitry by engaging in various processes such as synapse manipulation, elimination, maintenance, and plasticity (Hammond et al., 2018; Bohlen et al., 2019). Notably, there is increasing evidence to support microglial dysfunction in SCZ (Hercher et al., 2014; Bloomfield et al., 2016; Trepanier et al., 2016; De Picker et al., 2017; Sellgren et al., 2019; Uranova et al., 2020).

The major histocompatibility complex locus, situated on chromosome 6, exhibits the strongest association with SCZ (Stefansson et al., 2009; Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014). Within this region, a couple of genes have known roles in innate immunity. Complement 4A (*C4A*), located in the major histocompatibility complex locus, confers a strong association with SCZ. Increased levels of this protein directly correlated with SCZ risk (Sekar et al., 2016). In addition to their well-known role in immune defense, complement proteins also play a significant role in various stages of brain development, including neurogenesis, cellular migration, and synaptic development (Veerhuis et al., 2011; Lee et al., 2019). Over recent years, research has linked complement proteins to the process of microglia-mediated pruning of synapses, implying the direct link between *C4A* and SCZ pathology (Schafer et al., 2012; Hong et al., 2016). The molecular mechanism driving heightened expression of *C4A* to synaptic loss remains obscure, but mouse models overexpressing the neuroimmune gene have resulted in the localization of postsynaptic protein PSD-95 to microglial lysosomes. This process in turn leads to upregulated microglia-dependent synaptic engulfment (Comer et al., 2020). This excessive pruning leads to a reduction in synapse density, particularly during critical developmental periods such as adolescence (Germann et al., 2021; Zhuo et al., 2023). Studies using patient-derived neuronal cultures have also shown that microglia exhibit increased synapse elimination associated with these genetic variants (Sellgren et al., 2019; Yilmaz et al., 2021; Zhuo et al., 2023). The complement system's activation is pivotal in mediating microglial engulfment of synapses, with evidence suggesting that this process is altered in individuals with SCZ (Soteros and Sia, 2022).

Moreover, in schizophrenic patients, microglia are often found in a hyperactivated state, releasing pro-inflammatory cytokines (e.g., interleukin-6 and tumor necrosis factor- $\alpha$ ) and reactive oxygen species that can be neurotoxic and contribute to cognitive decline (Zhuo et al., 2023; Koskivi et al., 2024). This chronic neuroinflammatory state is thought to exacerbate synaptic loss by promoting excessive synaptic pruning (Hartmann et al., 2024).

In another study assessing C4 serum levels and AP medications response in a cohort of twenty-five SCZ patients with first-episode psychosis before prescription and followed by a 1-year post-treatment assessment, non-responders show significantly elevated baseline C4 levels compared to responders (Mondelli et al., 2020), suggesting the possibility of monitoring C4 baseline levels as a clinical tool for predicting medical outcome. However, the study focused on a limited number of genes, so the correlation between other immune markers and psychosis progression remains unclear. Nonetheless, *CSMD1*, a key regulator of C4, as well as genetic variants located in both *CSMD1* and *CSMD2* genes, are reported to be implicated in SCZ (Havik et al., 2011) and their dysfunction has been thought to be associated with cognitive decline (Athanasias et al., 2017).

More recently, a study conducted on SCZ using datasets from Gene Expression Omnibus and single-sample gene set enrichment analysis reported immunoregulatory genes with co-expression of gene modules determined through weighted gene correlation network analysis (Wu et al., 2024). The study aims to define the relationship between immunoregulatory reactions in SCZ development. Analysis of enriched bioprocesses related to immune genes with differential expression reveal key biological processes such as interferon-beta, IgG binding, and response to interferon-gamma, based on GO and Kyoto Encyclopedia of Genes and Genomes (Wu et al., 2024). A total of 112 genes exhibited significant variations in their expression levels between the two categories of immune genes, high immunity and low immunity subgroups consisting of 81 SCZ patients (Wu et al., 2024). *PLSCR1*, *FCGR1B*, *MT2A*, *IFITM1*, *GBP1*, *BST2*, *IFITM3*, *GBP2*, *CD44*, *FCER1G*, *HLA-DRA*, *FCGR2A*, *IFI16*, and *FCGR3B* are closely associated with interferon-beta response, IgG binding, and interferon-gamma response. The analysis of the protein-protein interaction network further identified eight hub genes implicated in immune infiltration in SCZ. These genes include *IFITM1*, *GBP1*, *BST2*, *IFITM3*, *GBP2*, *CD44*, *FCER1G*, *HLA-DRA*, *FCGR2A*, *IFI16*, and *FCGR3B*.

The mentioned study focused on the involvement of immune response abnormalities in the development of SCZ. Within the context of this study, two central genes, namely *IFITM1* and *IFITM3*, were identified as hub genes with potential relevance to the disease. The interferon-inducible transmembrane (IFITM/Fragilis) family of genes is responsible for the production of small proteins that are predominantly located in the plasma and endolysosomal membranes (Bailey et al., 2014; Zhao et al., 2018; Liao et al., 2019). IFITM proteins function as viral restriction factors,

inhibiting viral entry and replication within host cells. Higher expression of these proteins can result in a complex cascade of immune activation observed in SCZ (Severance and Yolken, 2016; Ermakov et al., 2022).

Studies have consistently shown that mRNA levels of *IFITM1* and *IFITM3* are significantly increased in the prefrontal cortex and hippocampus of individuals with SCZ compared to healthy controls (Hwang et al., 2013). For instance, studies reported a marked increase in *IFITM* expression correlating with higher levels of pro-inflammatory cytokines such as interleukin-6 and interferon- $\beta$ , which are known to induce *IFITM* expression (Hwang et al., 2013; Volk et al., 2015; Sanders et al., 2017). In addition, another study found that *IFITM* expression was significantly increased in a "high inflammation" SCZ subgroup compared to both a "low inflammation" SCZ subgroup and a "low inflammation" control subgroup (Cai et al., 2020). This suggests that *IFITM* expression may be particularly elevated in SCZ individuals who have a more pronounced inflammatory profile (Cai et al., 2020). Their upregulation may reflect a heightened immune response to perceived threats, which could lead to chronic inflammation. This persistent inflammatory state can disrupt normal neuronal function and contribute to the neurodevelopmental aspects of SCZ pathology (Horváth and Mirnics, 2014).

Additionally, prior research studies have demonstrated intricate and region-specific changes in the prefrontal cortex of SCZ patients concerning the increased transcript levels of interleukin-6 and interferon- $\beta$  which induce *IFITM* expression, and lower levels of *Schnurri-2*, an inhibitor of *IFITM* expression (Fillman et al., 2013; Siegel et al., 2014; Volk et al., 2015). Taken together, these findings collectively support the disorders reported in SCZ patients' brains.

#### Genes involved in lipid oxidation and transport

Characterization and understanding of the complexity of TRS have been attempted using proteogenomic approaches (Wei et al., 2023). The team leveraged on TRS-related proteome-wide association studies conducted on GWAS from CLOZUK and the Psychiatric Genomics Consortium which consists of a database including TRS participants ( $n=10,501$ ) and non-TRS participants ( $n=20,325$ ). With comparison to the reference datasets from human brain proteome from ROS/MAP, they identified a total of 41 differentially expressed proteins and two statistically significant proteins, CPT2 and APOL2 (Wei et al., 2023). By extending the analysis from gene-based to pathway-based, 14 gene ontology terms were identified leading to a single candidate pathway, lipid oxidation and inflammation, and mitochondria function which may play an essential role in TRS. A previous study supported the findings by reporting increased lipid peroxidation in TRS patients compared to the AP responsive group, suggesting that alterations in the lipid content of synaptic membranes may be responsible for neuronal dysfunction (Medina-Hernandez et al., 2007).

CPT2, carnitine palmitoyl transferase 2, localized in the inner mitochondrial membrane, has functions

of the transportation of long-chain fatty acids into the mitochondria matrix for oxidation. The role of lipid regulation in TRS has also been supported by several studies. Clozapine has been shown to modulate the AMPK-ACC-CPT1 pathway, the central lipid metabolism pathway, and affects the lipid levels in the rat frontal cortex (Kim et al., 2012). Moreover, SCZ patients were also reported to have alterations in lipid compositions in their frontal cortex (White et al., 2020).  $\beta$ -Oxidation, contributes to TRS, as indicated by increased levels of  $\beta$ -oxidation enzymes upon deletion of CTP2 in the nervous system (Kaul et al., 2024a). Genetic disorders affecting mitochondrial fatty  $\beta$ -oxidation have been associated with neurological disorders (Virmani et al., 2015; Merritt et al., 2018). Since CPT is expressed mainly in the brain regions, this could suggest that dysfunction in CTP2 may directly impact the central nervous system (Xie et al., 2016).

On the other hand, APOL2, primarily localized in the endoplasmic reticulum, is involved in cholesterol biosynthesis and trafficking and plays a role in inflammatory processes (Galindo-Moreno et al., 2014). Elevated APOL2 expression has been observed in SCZ patients, while polymorphism of this gene has been associated with risk in the disorder (Takahashi et al., 2008). APOL2 is expressed mainly in the brain (Luo et al., 2020), but more studies are required to further elucidate its precise function in the brain.

In a more recent GWAS study coupled with quantitative proteomic and metabolomic assay, and genotyping, comprising general SCZ patients without stratification of their drug responses, 20 differentially expressed proteins were identified (Kopylov et al., 2023). These include *ALS*, *A1AG1*, *PEDF*, *VTDB*, *CERU*, *APOB*, *APOH*, *FASN*, and *GPX3*. It was notable that almost half of the list consists of new hits for SCZ. Integration of multi omics layers with quantitative analysis for mapping molecular mechanisms relating to SCZ, lipid transport, and oxidative stress were two main events implicated in SCZ pathophysiology (Kopylov et al., 2023).

Lipid peroxidation which involves oxidative degradation of lipids mostly mediated by oxidative stress is one of the potential contributing factors leading to the pathophysiology of the disease. Increased levels of these lipid peroxide products such as malondialdehyde have been observed in SCZ patients (Guidara et al., 2020). These products can cause damage to cellular structure, including membranes and cellular organelles contributing to neuronal damage and inflammation, processes that are shown to be associated with the onset and progression of SCZ. Arachidonic acid, one of the well-known inflammatory lipid eicosanoids derived from polyunsaturated fatty acid, seems to be contributing to altered neuronal membrane dynamics, structure, fluidity, and permeability (Khan et al., 2002; Ayala et al., 2014). Specific behavioral symptoms of SCZ are shown to be associated with the impact of arachidonic acid alterations on the neurochemistry of deaminase, glutamate release, and the levels of endocannabinoids anandamide and 2-arachidonoylglycerol in circulation (Arvindakshan et al., 2003).

## Emerging Therapeutics for Schizophrenia and Treatment-Resistant Schizophrenia

The recent development of treatments for SCZ has moved away from targeting dopamine D2 receptors. A search on Cortellis (<https://clarivate.com>) for drugs targeting SCZ with drug pipeline target-based actions other than dopaminergic pathway modulators in Phase 2 development and higher generates a total of 33 records as of October 2024. Of these, 8 records are under pre-registration phase or in Phase 3 clinical trials. **Additional Table 1** shows the list of companies with drugs in Phase 2 or higher in development for active indications in SCZ. Regrettably, the transition from promising preclinical data and occasionally hopeful early clinical results into successful Phase 3 trials and subsequent new drug approvals for addressing SCZ symptom domains has been overwhelmingly lacking. Alpha-7 nicotinic acetylcholine receptor agonists such as encenicline did not demonstrate a statistically significant difference in the placebo at week 26 of analysis in Phase 3 trials (Brannan, 2019). Likewise, enhancement of glutamate signaling via glycine transporter type 1 inhibitor, d-amino acid oxidase inhibitor, and metabotropic glutamate mGluR2 and mGluR3 receptors agonists had failed to meet primary endpoint efficacy in Phase 2 and 3 trials (Adams et al., 2014; Bugarski-Kirola et al., 2016; Murthy et al., 2024). In a Phase 2 trial of another inhibitor of glycine transporter type 1, iclertin was found to be well tolerated and showed significant improvements in cognition leading to Phase 3 trials (Rosenbrock et al., 2023). Disappointingly, Boehringer Ingelheim announced in January 2025 that the topline results from the Phase 3 CONNEX trials did not meet the primary endpoints for cognitive impairments in schizophrenia for iclertin (Source: Boehringer Ingelheim Press Release). Some encouraging results of glutamate modulation in the treatment of SCZ come from the use of evenamide as an add-on treatment to AP in TRS patients, showing significant improvement in the PANSS total score at 6 weeks. Evenamide, developed by Newron Pharmaceuticals, is a selective inhibitor of voltage-gated sodium channels that normalizes excessive glutamate release believed to occur due to the hypofunction of NMDAR (Anand et al., 2023). It remains to be seen if evenamides demonstrate similar efficacy in Phase 3 trials.

Muscarinic acetylcholine receptor subtypes M1 and M4 are implicated in the pathology of SCZ. Targeting these receptors presents a promising opportunity for developing novel therapeutic strategies to treat the symptoms of SCZ, particularly those not effectively addressed by current AP. These findings are supported by preclinical and clinical research, as well as by molecular neuroimaging studies that have further elucidated the roles of muscarinic receptors in the molecular pathology of SCZ (Foster et al., 2021; Yohn et al., 2022; Dean et al., 2023). M4 muscarinic receptor in the brain reduces the release of acetylcholine from interneurons, leading to decreased dopamine transmission and heightened glutamatergic neurotransmission (Kantrowitz et al., 2023). Cobenfy, previously known as KarXT (xanomeline-trospium) originally developed by Karuna Therapeutics is a first-in-

class M1/M4 muscarinic receptor agonist with the peripherally restricted muscarinic receptor antagonist trospium chloride, has demonstrated efficacy and an improved safety profile as compared to traditional AP (Correll et al., 2022). Cobenfy has recently been approved by the Food, Drug and Administration based on two pivotal phase 3 trials that met the primary end-point with about a 21-point reduction in PANSS score (Kingwell, 2024). Data from EMERGENT-3 trial showed a statistically significant and clinically meaningful reduction of 8.4 points in the PANSS total score among participants who received KarXT for 5 weeks (−20.6 points) compared to those who received a placebo (−12.2 points) (Kaul et al., 2024a). Data from EMERGENT-2 trial demonstrated favorable reduction of PANSS total score from baseline to week 5 among participants who received KarXT (−21.2 points) *versus* placebo (−11.6 points) (Kaul et al., 2024b). In both trials, common adverse events experienced by KarXT include constipation, dyspepsia, vomiting, and nausea. There were no significant differences in adverse event-related discontinuation rates between KarXT and placebo, and the measures of extrapyramidal symptoms, including weight gain, were comparable across both treatment groups (Kaul et al., 2024b). A second muscarinic agent CVL-231 (Emraclidine) developed by Cerevel Therapeutics and acquired by AbbVie functions as a positive allosteric modulator that selectively targets the M4 muscarinic receptor. It exhibited a favorable side-effect profile in Phase 1b trial and advanced to Phase 2 developments (Krystal et al., 2022; Kantrowitz et al., 2023). However, recent Phase 2 clinical trial results from EMPOWER-1 and EMPOWER-2 did not meet their primary endpoint for Emraclidine (source: AbbVie News Center). These disappointing findings suggest that selective M4 receptor agonism alone may be insufficient for meaningful clinical improvement, whereas the combined activation of M1 and M4 receptors (as seen with KarXT) may be more effective. Moving forward, we hypothesize those muscarinic receptor-targeted therapies for schizophrenia will likely require a polypharmacological approach, as single-receptor modulation appears unlikely to yield optimal outcomes.

Other than muscarinic receptor agonism, Trace amine-associated receptor 1 has emerged as another therapeutic target for SCZ (Dedic et al., 2021). The mechanism of action of TAAR1 in SCZ involves modulating dopaminergic neurotransmission. By targeting TAAR1, the aim is to effectively treat the various symptoms of SCZ, including positive and negative symptoms, as well as cognitive impairments, with fewer overall side effects than current AP medications (Nair et al., 2022; Sifas et al., 2024). TAAR1 agonism promotes heterodimerization of the TAAR1 receptor with pre- and postsynaptic D2 receptors leading to the internalization of receptors and subsequently reducing presynaptic dopamine synthesis (Kantrowitz et al., 2023). Unfortunately, in Phase 3 trials - Developing Innovative Approaches for Mental Disorders (DIAMOND) 1 and DIAMOND 2, multicenter, randomized, double-blind, parallel-group, fixed-dose clinical studies, administering Ulotaront, a dual TAAR1 and 5-HT1AR agonist developed by Sumitomo Pharma (Sumitomo News Room), once daily to adults with SCZ was shown not to be superior to placebo (Zilberg et al., 2024).

Recent insights from a comprehensive systematic review and meta-analysis of human and non-human data on TAAR1 agonism for psychosis suggest that TAAR1 agonists may be considered less effective than currently available dopamine D2 receptor antagonists for treating SCZ, as they are suggested to have potentially smaller positive effects compared to other AP (Sifas et al., 2024).

Recently, there has also been significant industry effort in developing PDE10A inhibitors for SCZ (Menniti et al., 2021). This focus is due to the importance of striatal dopamine signaling in SCZ, where phosphodiesterases (PDE), including PDE10A, play a role in modulating dopamine receptor-associated second messenger machinery, which is closely linked to drug-induced gene regulation in the striatum. PDE10A inhibitors work by blocking the activity of the phosphodiesterase 10A enzyme, responsible for breaking down signaling molecules such as 3' cyclic adenosine 3',5'-monophosphate (cAMP) and cyclic guanosine 3',5'-monophosphate (cGMP). By inhibiting PDE10A, these inhibitors increase the levels of cAMP and cGMP, affecting cellular communication and signaling in specific neurons, such as the medium spiny neurons in the striatum (Bonate et al., 2022). The increased cyclic nucleotide levels in these neurons may impact dopamine-mediated signaling and contribute to the modulation of striatal function related to action selection and behavioral control (Amin et al., 2021; Menniti et al., 2021). PDE10A inhibition has been shown to produce AP-like effects in preclinical rat models of SCZ and has also demonstrated cognitive enhancement, particularly in domains such as recognition memory, attention, impulsivity, working memory, and executive function (Shiraishi et al., 2016; Arakawa and Maehara, 2020; Harada et al., 2020). Supporting PDE10A inhibition in improving PANSS scores in acute SCZ, a randomized, double-blind, placebo- and active-controlled Phase 2a trial evaluated the PDE10A inhibitor MK-8189 developed by Merck & Co., Inc., Rahway, NJ, USA. The study demonstrated a trend towards improvement in PANSS total score after 4 weeks compared to placebo (difference = −4.7 points,  $P = 0.074$ ), although it was not superior to risperidone (difference compared to placebo = −7.3 points,  $P = 0.033$ ). Nevertheless, MK-8189 showed lower discontinuation rates due to adverse events and significant weight loss in obese subjects compared to risperidone (Mukai et al., 2024). However, results from clinical trials of other PDE10A inhibitors have been mixed. In a randomized, parallel-group, placebo-controlled Phase 2 study by Takeda that evaluated the phosphodiesterase 10A inhibitor TAK-063 compared to placebo in adults with acutely exacerbated symptoms of SCZ, the study did not meet the primary endpoint, as the least-squares mean difference in change from baseline in PANSS total score at week 6 between TAK-063 and placebo was not statistically significant (Macek et al., 2019). Similarly, results from another Phase 2 study by Pfizer to evaluate the efficacy of PF-02545920 compared to placebo in treating acute exacerbation of SCZ, showed that at day 28, neither dose of PF-02545920 was significantly different from placebo on the primary endpoint of change from baseline in total PANSS score (Walling et al., 2019). Understanding the specific reasons

for the lack of efficacy of some of the PDE10A inhibitors could provide valuable insights for future drug development in the treatment of psychosis and SCZ.

## Outlook and Conclusion

Current limitations in SCZ research exist across multiple domains. Emphasis on single neurotransmitter systems, such as dopamine, fails to capture the complex interplay between dopaminergic, glutamatergic, serotonergic, and GABAergic pathways. Clinically, overlapping symptom presentations, particularly in early-onset cases and with predominantly negative symptoms, contribute to diagnostic ambiguity and potential misdiagnosis. Mechanistically, a lack of comprehensive understanding remains, particularly in immune dysfunction, lipid metabolism abnormalities, and genetic risk partitioning, which hinder the development of targeted treatments. These limitations highlight the need for more comprehensive, integrated, and multidisciplinary approaches that address the complexity and heterogeneity of SCZ.

Although AP remain the cornerstone of treatment, their limited efficacy and associated adverse effects underscore the urgent need for novel therapeutics that target mechanisms beyond the traditional dopamine D2 receptor (Remington et al., 2015b). Promising emerging strategies, such as targeting muscarinic acetylcholine receptor subtypes M1 and M4, as well as the development of PDE10A inhibitors, constitute ongoing research efforts to address these challenges.

**Author contributions:** *JIEC conceptualized the manuscript; DXEL, SY, and CZYA drafted the manuscript; SY, DXEL, and CZYA created figures; SY constructed the table. All authors contributed to revising the manuscript and approved the final version of the manuscript.*

**Conflicts of interest:** *JL had received honoraria and served as a consultant or advisory board member from Otsuka, Janssen, Lundbeck, Sumitomo Pharmaceuticals, Boehringer Ingelheim, ThoughtFull World Pte. Ltd. and Singapore Deep-Tech Alliance. DXEL, SY, CZYA, and AZF are employees or contractors of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD). No conflicts of interest exist between Otsuka, Janssen, Lundbeck, Sumitomo Pharmaceuticals, Boehringer Ingelheim, ThoughtFull World Pte. Ltd., Singapore Deep-Tech Alliance, and Merck Sharp & Dohme LLC and publication of this paper. The other authors declare no conflicts of interest.*

**Data availability statement:** *Not applicable.*

**Open access statement:** *This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.*

**Additional file:**

**Additional Table 1:** *A list of companies with Phase 2 or higher development with active indications for treatment of schizophrenia.*

## References

- Adams DH, Zhang L, Millen BA, Kinon BJ, Gomez JC (2014) Pomaglumetad methionil (LY2140023 monohydrate) and aripiprazole in patients with schizophrenia: A phase 3, multicenter, double-blind comparison. *Schizophr Res Treatment* 2014:758212.
- Adams JP, Sweatt JD (2002) Molecular psychology: roles for the ERK MAP kinase cascade in memory. *Annu Rev Pharmacol Toxicol* 42:135-163.
- Adams SV, Winterer J, Müller W (2004) Muscarinic signaling is required for spike-pairing induction of long-term potentiation at rat Schaffer collateral-CA1 synapses. *Hippocampus* 14:413-416.
- Akhondzadeh S (2001) The 5-HT hypothesis of schizophrenia. *IDrugs* 4:295-300.
- Amin HS, Parikh PK, Gbate MD (2021) Medicinal chemistry strategies for the development of phosphodiesterase 10A (PDE10A) inhibitors - An update of recent progress. *Eur J Med Chem* 214:113155.
- Amoretti S, Rabelo-da-Ponte FD, Rosa AR, Mezquida G, Sánchez-Torres AM, Fraguas D, Cabrera B, Lobo A, González-Pinto A, Pina-Camacho L, Corripio I, Vieta E, Torrent C, de la Serna E, Bergé D, Bioque M, Garriga M, Serra M, Cuesta MJ, Bernardo M; PEPs Group (2021) Cognitive clusters in first-episode psychosis. *Schizophr Res* 237:31-39.
- An der Heiden W, Leber A, Hafner H (2016) Negative symptoms and their association with depressive symptoms in the long-term course of schizophrenia. *Eur Arch Psychiatry Clin Neurosci* 266:387-396.
- Anand R, Turolla A, Chinellato G, Roy A, Hartman RD (2023) Phase 2 results indicate evenamide, a selective modulator of glutamate release, is associated with clinically important long-term efficacy when added to an antipsychotic in patients with treatment-resistant schizophrenia. *Int J Neuropsychopharmacol* 26:523-528.
- Andrade A, Hope J, Allen A, Yorgan V, Lipscombe D, Pan JQ (2016) A rare schizophrenia risk variant of CACNA1B disrupts Ca(V)3.3 channel activity. *Sci Rep* 6:34233.
- Arakawa K, Maehara S (2020) Combination of the phosphodiesterase 10A inhibitor, MR1916 with risperidone shows additive antipsychotic-like effects without affecting cognitive enhancement and cataleptic effects in rats. *Neuropsychopharm Rep* 40:190-195.
- Arndt S, Andreasen NC, Flaum M, Miller D, Nopoulos P (1995) A longitudinal study of symptom dimensions in schizophrenia. Prediction and patterns of change. *Arch Gen Psychiatry* 52:352-360.
- Arvindakshan M, Sitasawad S, Debsikdar V, Gbate M, Evans D, Horrobin DF, Bennett C, Ranjekar PK, Mahadik SP (2003) Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. *Biol Psychiatry* 53:56-64.
- Athanasiu L, Giddaluru S, Fernandes C, Christoforou A, Reinvang I, Lundervold AJ, Nilsson LG, Kauppi K, Adolfsson R, Eriksson E, Sundet K, Djurovic S, Espeseth T, Nyberg L, Steen VM, Andreassen OA, Le Hellard S (2017) A genetic association study of CSMD1 and CSMD2 with cognitive function. *Brain Behav Immun* 61:209-216.
- Ayala A, Muñoz MF, Argüelles S (2014) Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. *Oxid Med Cell Longev* 2014:360438.
- Ayata P, Badimon A, Strasburger HJ, Duff MK, Montgomery SE, Loh YE, Ebert A, Pimenova AA, Ramirez BR, Chan AT, Sullivan JM, Purushothaman I, Scarpa JR, Goate AM, Busslinger M, Shen L, Losic B, Schaefer A (2018) Epigenetic regulation of brain region-specific microglia clearance activity. *Nat Neurosci* 21:1049-1060.
- Bailey CC, Zhong G, Huang IC, Farzan M (2014) IFITM-family proteins: the cell's first line of antiviral defense. *Annu Rev Virol* 1:261-283.
- Bakken TL (2021) Behavioural equivalents of schizophrenia in people with intellectual disability and autism spectrum disorder: a selective review. *Int J Dev Disabil* 67:310-317.
- Bloomfield PS, Selvaraj S, Veronese M, Rizzo G, Bertoldo A, Owen DR, Bloomfield MA, Bonaldi I, Kalk N, Turkheimer F, McGuire P, de Paola V, Howes OD (2016) Microglial activity in people at ultra high risk of psychosis and in schizophrenia: an [(11)C]PBR28 PET brain imaging study. *Am J Psychiatry* 173:44-52.
- Bohlen CJ, Friedman BA, Dejanovic B, Sheng M (2019) Microglia in brain development, homeostasis, and neurodegeneration. *Annu Rev Genet* 53:263-288.
- Bonate R, Kurek G, Hrabak M, Patterson S, Padovan-Neto F, West AR, Steiner H (2022) Phosphodiesterase 10A (PDE10A): regulator of dopamine agonist-induced gene expression in the striatum. *Cells* 11:2214.
- Boyd KN, Mailman RB (2012) Dopamine receptor signaling and current and future antipsychotic drugs. *Handb Exp Pharmacol* doi: 10.1007/978-3-642-25761-2\_3.
- Boyer P, Phillips JL, Rousseau FL, Ilivitsky S (2007) Hippocampal abnormalities and memory deficits: new evidence of a strong pathophysiological link in schizophrenia. *Brain Res Rev* 54:92-112.
- Bradley SR, Lameh J, Ohrmund L, Son T, Bajpai A, Nguyen D, Friberg M, Burstein ES, Spalding TA, Ott TR, Schiffer HH, Tabatabaei A, McFarland K, Davis RE, Bonhaus DW (2010) AC-260584, an orally bioavailable M(1) muscarinic receptor allosteric agonist, improves cognitive performance in an animal model. *Neuropharmacology* 58:365-373.
- Brannan S (2019) Two global phase III trials of encenidine for cognitive impairment in chronic schizophrenia patients: red flags and lessons learned. *Schizophrenia Bulletin* 45:S141-142.
- Brasso C, Bellino S, Bozzatello P, Montemagni C, Nobili MGA, Sgro R, Rocca P (2023) Second generation long-acting injectable antipsychotics in schizophrenia: the patient's subjective quality of life, well-being, and satisfaction. *J Clin Med* 12:6985.
- Brisch R, Saniotis A, Wolf R, Bielau H, Bernstein HG, Steiner J, Bogerts B, Braun K, Jankowski Z, Kumaratilake J, Henneberg M, Gos T (2014) The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue. *Front Psychiatry* 5:47.
- Brodsky H, Sachdev P, Koschera A, Monk D, Cullen B (2003) Long-term outcome of late-onset schizophrenia: 5-year follow-up study. *Br J Psychiatry* 183:213-219.
- Buchanan KA, Petrovic MM, Chamberlain SE, Marrión NV, Mellor JR (2010) Facilitation of long-term potentiation by muscarinic M(1) receptors is mediated by inhibition of SK channels. *Neuron* 68:948-963.
- Buck SA, Quincy Erickson-Oberg M, Logan RW, Freyberg Z (2022) Relevance of interactions between dopamine and glutamate neurotransmission in schizophrenia. *Mol Psychiatry* 27:3583-3591.
- Buckley PF (2020) Treatment-resistant schizophrenia. *Focus (Am Psychiatr Publ)* 18:364-367.
- Bugarski-Kirila D, Iwata N, Sameljak S, Reid C, Blaettler T, Millar L, Marques TR, Garibaldi G, Kapur S (2016) Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme. *Lancet Psychiat* 3:1115-1128.
- Burdick KE, Goldberg JF, Harrow M, Faull RN, Malhotra AK (2006) Neurocognition as a stable endophenotype in bipolar disorder and schizophrenia. *J Nerv Ment Dis* 194:255-260.
- Butcher I, Berry K, Haddock G (2020) Understanding individuals' subjective experiences of negative symptoms of schizophrenia: a qualitative study. *Br J Clin Psychol* 59:319-334.
- Cai HQ, Catts VS, Webster MJ, Galletly C, Liu D, O'Donnell M, Weickert TW, Weickert CS (2020) Increased macrophages and changed brain endothelial cell gene expression in the frontal cortex of people with schizophrenia displaying inflammation. *Mol Psychiatry* 25:761-775.

- Cheng W, Frei O, van der Meer D, Wang Y, O'Connell KS, Chu Y, Bahrami S, Shadrin AA, Alnæs D, Hindley GFL, Lin A, Karadag N, Fan CC, Westlye LT, Kaufmann T, Molden E, Dale AM, Djurovic S, Smeland OB, Andreassen OA (2021) Genetic association between schizophrenia and cortical brain surface area and thickness. *JAMA Psychiatry* 78:1020-1030.
- Chouinard G, Samaha AN, Chouinard VA, Peretti CS, Kanahara N, Takase M, Iyo M (2017) Antipsychotic-induced dopamine supersensitivity psychosis: pharmacology, criteria, and therapy. *Psychother Psychosom* 86:189-219.
- Ciranna L (2006) Serotonin as a modulator of glutamate- and GABA-mediated neurotransmission. *Curr Neuropharmacol* 4:101-114.
- Cobia DJ, Smith MJ, Wang L, Csernansky JG (2012) Longitudinal progression of frontal and temporal lobe changes in schizophrenia. *Schizophr Res* 139:1-6.
- Collaborators GBDMD (2022) Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Psychiatr* 9:137-150.
- Comer AL, Jinadasa T, Sriram B, Phadke RA, Kretsge LN, Nguyen TPH, Antognetti G, Gilbert JP, Lee J, Newmark ER, Hausmann FS, Rosenthal S, Liu Kot K, Liu Y, Yen WW, Dejanovic B, Cruz-Martin A (2020) Increased expression of schizophrenia-associated gene C4 leads to hypoconnectivity of prefrontal cortex and reduced social interaction. *PLoS Biol* 18:e3000604.
- Correll CU, Schooler NR (2020) Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. *Neuropsychiatr Dis Treat* 16:519-534.
- Correll CU, Howes OD (2021) Treatment-resistant schizophrenia: definition, predictors, and therapy options. *J Clin Psychiatry* 82:MY20096AHC1C.
- Correll CU, Angelov AS, Miller AC, Weiden PJ, Brannan SK (2022) Safety and tolerability of KarXT (xanomeline-tropium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia. *Schizophrenia* (Heidelberg) 8:109.
- Courtillot E, Menezes EC, Teixeira CM (2021) Serotonergic regulation of the dopaminergic system: Implications for reward-related functions. *Neurosci Biobehav Rev* 128:282-293.
- Cross-Disorder Group of the Psychiatric Genomics Consortium (2013) Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. *Lancet* 381:1371-1379.
- Curtis D, Vine AE, McQuillin A, Bass NJ, Pereira A, Kandaswamy R, Lawrence J, Anjorin A, Choudhury K, Datta SR, Puri V, Krasucki R, Pimm J, Thirumalai S, Quesada D, Gurling HM (2011) Case-case genome-wide association analysis shows markers differentially associated with schizophrenia and bipolar disorder and implicates calcium channel genes. *Psychiatr Genet* 21:1-4.
- Dasari S, Gullledge AT (2011) M1 and M4 receptors modulate hippocampal pyramidal neurons. *J Neurophysiol* 105:779-792.
- De Deurwaerdère P, Chagraoui A, Di Giovanni G (2021) Serotonin/dopamine interaction: Electrophysiological and neurochemical evidence. *Prog Brain Res* 261:161-264.
- de Leeuw CA, Mooij JM, Heskes T, Posthuma D (2015) MAGMA: generalized gene-set analysis of GWAS data. *PLOS Computational Biology* 11:e1004219.
- De Picker LJ, Morris M, Chance SA, Boche D (2017) Microglia and brain plasticity in acute psychosis and schizophrenia illness course: a meta-review. *Front Psychiatry* 8:238.
- de Winter L, Vermeulen JM, Couwenbergh C, van Weeghel J, Hasson-Ohayon I, Mulder CL, Boonstra N, Veling W, de Haan L (2023) Short- and long-term changes in symptom dimensions among patients with schizophrenia spectrum disorders and different durations of illness: a meta-analysis. *J Psychiatr Res* 164:416-439.
- Deacon BJ (2013) The biomedical model of mental disorder: a critical analysis of its validity, utility, and effects on psychotherapy research. *Clin Psychol Rev* 33:846-861.
- Dean B (2001) A predicted cortical serotonergic/cholinergic/GABAergic interface as a site of pathology in schizophrenia. *Clin Exp Pharmacol Physiol* 28:74-78.
- Dean B, Bakker G, Ueda HR, Tobin AB, Brown A, Kanaan RAA (2023) A growing understanding of the role of muscarinic receptors in the molecular pathology and treatment of schizophrenia. *Front Cell Neurosci* 17:1124333.
- Dedic N, Dworak H, Zeni C, Rutigliano G, Howes OD (2021) Therapeutic potential of TAAR1 agonists in schizophrenia: evidence from preclinical models and clinical studies. *Int J Mol Sci* 22:13185.
- Demjaha A, Egerton A, Murray RM, Kapur S, Howes OD, Stone JM, McGuire PK (2014) Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. *Biol Psychiatry* 75:e11-13.
- Demjaha A, Lappin JM, Stahl D, Patel MX, McCabe JH, Howes OD, Heslin M, Reininghaus UA, Donoghue K, Lomas B, Charalambides M, Onyejiaka A, Fearon P, Jones P, Doody G, Morgan C, Dazzan P, Murray RM (2017) Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. *Psychol Med* 47:1981-1989.
- Deng C, Dean B (2013) Mapping the pathophysiology of schizophrenia: interactions between multiple cellular pathways. *Front Cell Neurosci* 7:238.
- Dickinson BA, Jo J, Seok H, Son GH, Whitcomb DJ, Davies CH, Sheng M, Collingridge GL, Cho K (2009) A novel mechanism of hippocampal LTD involving muscarinic receptor-triggered interactions between AMPARs, GRIP and liprin-alpha. *Mol Brain* 2:18.
- Diseases GBD, Injuries C (2020) Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* 396:1204-1222.
- Dixon L (2017) What it will take to make coordinated specialty care available to anyone experiencing early schizophrenia: getting over the hump. *JAMA Psychiatry* 74:7-8.
- Emsley R, Nuamah I, Hough D, Gopal S (2012) Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. *Schizophr Res* 138:29-34.
- Ermakov EA, Melamud MM, Buneva VN, Ivanova SA (2022) Immune system abnormalities in schizophrenia: an integrative view and translational perspectives. *Front Psychiatry* 13:880568.
- Felder CC, Porter AC, Skillman TL, Zhang L, Bymaster FP, Nathanson NM, Hamilton SE, Gomez J, Wess J, McKinzie DL (2001) Elucidating the role of muscarinic receptors in psychosis. *Life Sci* 68:2605-2613.
- Fernandez-Miranda JJ, Diaz-Fernandez S, Cepeda-Piorno FJ, Lopez-Munoz F (2024) Long-acting injectable second-generation antipsychotics in seriously ill patients with schizophrenia: doses, plasma levels, and treatment outcomes. *Biomedicines* 12:165.
- Fillman SG, Cloonan N, Catts VS, Miller LC, Wong J, McCrossin T, Cairns M, Weickert CS (2013) Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. *Mol Psychiatry* 18:206-214.
- First MB (2024) Psychiatric classification. In: Tasman's Psychiatry (Tasman A, Riba MB, Alarcón RD, Alfonso CA, Kanba S, Lecic-Tosevski D, Ndeti DM, Ng CH, Schulze TG, eds), pp 1465-1491. Cham: Springer International Publishing.
- Firth J, et al. (2020) A meta-review of "lifestyle psychiatry": the role of exercise, smoking, diet and sleep in the prevention and treatment of mental disorders. *World Psychiatry* 19:360-380.
- Föcking M, Doyle B, Munawar N, Dillon ET, Cotter D, Cagney G (2019) Epigenetic factors in schizophrenia: mechanisms and experimental approaches. *Mol Neuropsychiatry* 5:6-12.
- Foster DJ, Bryant ZK, Conn PJ (2021) Targeting muscarinic receptors to treat schizophrenia. *Behav Brain Res* 405:113201.
- Foster DJ, Wilson JM, Remke DH, Mahmood MS, Uddin MJ, Wess J, Patel S, Marnett LJ, Niswender CM, Jones CK, Xiang Z, Lindsley CW, Rook JM, Conn PJ (2016) Antipsychotic-like effects of M4 positive allosteric modulators are mediated by CB2 receptor-dependent inhibition of dopamine release. *Neuron* 91:1244-1252.
- Friedman JI, Harvey PD, Coleman T, Moriarty PJ, Bowie C, Parrrella M, White L, Adler D, Davis KL (2001) Six-year follow-up study of cognitive and functional status across the lifespan in schizophrenia: a comparison with Alzheimer's disease and normal aging. *Am J Psychiatry* 158:1441-1448.
- Fromer M, et al. (2014) De novo mutations in schizophrenia implicate synaptic networks. *Nature* 506:179-184.
- Frydecka D, Krzystek-Korpacz M, Lubeiro A, Stramecki F, Stanczykiewicz B, Beszlej JA, Piotrowski P, Kotowicz K, Szewczuk-Bogusławska M, Pawlak-Adamska E, Misiak B (2018) Profiling inflammatory signatures of schizophrenia: a cross-sectional and meta-analysis study. *Brain Behav Immun* 71:28-36.
- Fujigaki H, Mouri A, Yamamoto Y, Nabeshima T, Saito K (2019) Linking phencyclidine intoxication to the tryptophan-kynurenine pathway: therapeutic implications for schizophrenia. *Neurochem Int* 125:1-6.
- Galderisi S, Kaiser S, Bitter I, Nordentoft M, Mucci A, Sabe M, Giordano GM, Nielsen MO, Glenthøj LB, Pezzella P, Falkai P, Döhlfus S, Gaebel W (2021) EPA guidance on treatment of negative symptoms in schizophrenia. *Eur Psychiatry* 64:e21.
- Galderisi S, et al. (2014) The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. *World Psychiatry* 13:275-287.
- Galderisi S, et al. (2020) The interplay among psychopathology, personal resources, context-related factors and real-life functioning in schizophrenia: stability in relationships after 4 years and differences in network structure between recovered and non-recovered patients. *World Psychiatry* 19:81-91.
- Galindo-Moreno J, Iurlaro R, El Mjiyad N, Diez-Perez J, Gabaldon T, Munoz-Pinedo C (2014) Apolipoprotein L2 contains a BH3-like domain but it does not behave as a BH3-only protein. *Cell Death Dis* 5:e1275.
- Galloway DA, Phillips AEM, Owen DRJ, Moore CS (2019) Phagocytosis in the brain: homeostasis and disease. *Front Immunol* 10:790.
- Gammon D, Cheng C, Volkovskaia A, Baker GB, Dursun SM (2021) Clozapine: why is it so uniquely effective in the treatment of a range of neuropsychiatric disorders? *Biomolecules* 11:1030.
- Geddes J, Freemantle N, Harrison P, Bebbington P (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. *BMJ* 321:1371-1376.
- Gerber DJ, Sotnikova TD, Gainetdinov RR, Huang SY, Caron MG, Tonegawa S (2001) Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. *Proc Natl Acad Sci U S A* 98:15312-15317.
- Germann M, Brederoo SG, Sommer IEC (2021) Abnormal synaptic pruning during adolescence underlying the development of psychotic disorders. *Curr Opin Psychiatry* 34:222-227.
- Goff DC (2021) The pharmacologic treatment of schizophrenia-2021. *JAMA* 325:175-176.
- Goghari VM, Harrow M, Grossman LS, Rosen C (2013) A 20-year multi-follow-up of hallucinations in schizophrenia, other psychotic, and mood disorders. *Psychol Med* 43:1151-1160.
- Gomez J, Zhang L, Kostenis E, Felder C, Bymaster F, Brodtkin J, Shannon H, Xia B, Deng C, Wess J (1999) Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice. *Proc Natl Acad Sci U S A* 96:10483-10488.





- Guan F, Zhang T, Liu X, Han W, Lin H, Li L, Chen G, Li T (2016) Evaluation of voltage-dependent calcium channel gamma gene families identified several novel potential susceptible genes to schizophrenia. *Sci Rep* 6:24914.
- Guidara W, Messedi M, Naifar M, Maalej M, Grayaa S, Omri S, Ben Thabet J, Maalej M, Charfi N, Ayadi F (2020) Predictive value of oxidative stress biomarkers in drug-free patients with schizophrenia and schizoaffective disorder. *Psychiatry Res* 293:113467.
- Gur RE, Cowell P, Turetsky BI, Gallacher F, Cannon T, Bilker W, Gur RC (1998) A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures. *Arch Gen Psychiatry* 55:145-152.
- Habtbetwold TD, Tiles-Sar N, Liemburg EJ, Sandhu AK, Islam MA, Boezen HM, Bruggeman R, Alizadeh BZ (2023) Six-year trajectories and associated factors of positive and negative symptoms in schizophrenia patients, siblings, and controls: Genetic Risk and Outcome of Psychosis (GROUP) study. *Sci Rep* 13:9391.
- Hamilton SE, Nathanson NM (2001) The M1 receptor is required for muscarinic activation of mitogen-activated protein (MAP) kinase in murine cerebral cortical neurons. *J Biol Chem* 276:15850-15853.
- Hammond TR, Robinton D, Stevens B (2018) Microglia and the brain: complementary partners in development and disease. *Annu Rev Cell Dev Biol* 34:523-544.
- Harada A, Kaushal N, Suzuki K, Nakatani A, Bobkov K, Vekich JA, Doyle JP, Kimura H (2020) Balanced activation of striatal output pathways by faster off-rate PDE10A inhibitors elicits not only antipsychotic-like effects but also procognitive effects in rodents. *Int J Neuropsychoph* 23:96-107.
- Harrow M, Jobe TH, Faull RN, Yang J (2017) A 20-year multi-followup longitudinal study assessing whether antipsychotic medications contribute to work functioning in schizophrenia. *Psychiatry Res* 256:267-274.
- Hartmann SM, Heider J, Wüst R, Fallgatter AJ, Volkmer H (2024) Microglia-neuron interactions in schizophrenia. *Front Cell Neurosci* 18:1345349.
- Harvey PD, Strassnig M (2012) Predicting the severity of everyday functional disability in people with schizophrenia: cognitive deficits, functional capacity, symptoms, and health status. *World Psychiatry* 11:73-79.
- Harvey PD, Bosia M, Cavallaro R, Howes OD, Kahn RS, Leucht S, Müller DR, Penadés R, Vita A (2022) Cognitive dysfunction in schizophrenia: an expert group paper on the current state of the art. *Schizophr Res Cogn* 29:100249.
- Havik B, et al. (2011) The complement control-related genes CSMD1 and CSMD2 associate to schizophrenia. *Biol Psychiatry* 70:35-42.
- He K, An Z, Wang Q, Li T, Li Z, Chen J, Li W, Wang T, Ji J, Feng G, Lin H, Yi Q, Shi Y (2014) CACNA1C, schizophrenia and major depressive disorder in the Han Chinese population. *Br J Psychiatry* 204:36-39.
- He Y, Tanaka A, Kishi T, Li Y, Matsunaga M, Tanihara S, Iwata N, Ota A (2022) Recent findings on subjective well-being and physical, psychiatric, and social comorbidities in individuals with schizophrenia: a literature review. *Neuropsychopharmacol Rep* 42:430-436.
- Heilbronner U, Samara M, Leucht S, Falkai P, Schulze TG (2016) The longitudinal course of schizophrenia across the lifespan: clinical, cognitive, and neurobiological aspects. *Harv Rev Psychiatry* 24:118-128.
- Hercher C, Chopra V, Beasley CL (2014) Evidence for morphological alterations in prefrontal white matter glia in schizophrenia and bipolar disorder. *J Psychiatry Neurosci* 39:376-385.
- Herzog LE, Wang L, Yu E, Choi S, Farsi Z, Song BJ, Pan JQ, Sheng M (2023) Mouse mutants in schizophrenia risk genes GRIN2A and AKAP11 show EEG abnormalities in common with schizophrenia patients. *Transl Psychiatry* 13:92.
- Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, Merry KM, Shi Q, Rosenthal A, Barres BA, Lemere CA, Selkoe DJ, Stevens B (2016) Complement and microglia mediate early synapse loss in Alzheimer mouse models. *Science* 352:712-716.
- Horváth S, Mirmics K (2014) Immune system disturbances in schizophrenia. *Biol Psychiatry* 75:316-323.
- Hoshi N (2020) M-current suppression, seizures and lipid metabolism: a potential link between neuronal Kv7 channel regulation and dietary therapies for epilepsy. *Front Physiol* 11:513.
- Howes O, McCutcheon R, Stone J (2015) Glutamate and dopamine in schizophrenia: an update for the 21st century. *J Psychopharmacol* 29:97-115.
- Howes OD, Kapur S (2009) The dopamine hypothesis of schizophrenia: version III--the final common pathway. *Schizophr Bull* 35:549-562.
- Hunt DL, Castillo PE (2012) Synaptic plasticity of NMDA receptors: mechanisms and functional implications. *Curr Opin Neurobiol* 22:496-508.
- Hurlmann R, Matusch A, Kuhn KU, Berning J, Elmenhorst D, Winz O, Kolsch H, Zilles K, Wagner M, Maier W, Bauer A (2008) 5-HT2A receptor density is decreased in the at-risk mental state. *Psychopharmacology* 195:579-590.
- Hwang Y, Kim J, Shin JY, Kim JI, Seo JS, Webster MJ, Lee D, Kim S (2013) Gene expression profiling by mRNA sequencing reveals increased expression of immune/inflammation-related genes in the hippocampus of individuals with schizophrenia. *Transl Psychiatry* 3:e321.
- Irish Schizophrenia Genomics Consortium and the Wellcome Trust Case Control Consortium 2 (2012) Genome-wide association study implicates HLA-C\*01:02 as a risk factor at the major histocompatibility complex locus in schizophrenia. *Biol Psychiatry* 72:620-628.
- Jauhar S, Johnstone M, McKenna PJ (2022) Schizophrenia. *Lancet* 399:473-486.
- Jauhar S, Veronese M, Nour MM, Rogdaki M, Hathway P, Turkheimer FE, Stone J, Egerton A, McGuire P, Kapur S, Howes OD (2019) Determinants of treatment response in first-episode psychosis: an (18F)-DOPA PET study. *Mol Psychiatry* 24:1502-1512.
- Kaliso L, Michalec J, Dechterenko F, Silhan P, Hyza M, Chlebovcova M, Brenova M, Bezdicek O (2023) Impact of cognitive performance and negative symptoms on psychosocial functioning in Czech schizophrenia patients. *Schizophrenia* 9:43.
- Kantrowitz JT, Correll CU, Jain R, Cutler AJ (2023) New developments in the treatment of schizophrenia: an expert roundtable. *Int J Neuropsychopharmacol* 26:322-330.
- Karr JE, Graham RB, Hofer SM, Muniz-Terrera G (2018) When does cognitive decline begin? A systematic review of change point studies on accelerated decline in cognitive and neurological outcomes preceding mild cognitive impairment, dementia, and death. *Psychol Aging* 33:195-218.
- Kaul I, Sawchak S, Walling DP, Tamminga CA, Breier A, Zhu H, Miller AC, Paul SM, Brannan SK (2024a) Efficacy and safety of xanomeline-tropium chloride in schizophrenia: a randomized clinical trial. *JAMA Psychiatry* 81:749-756.
- Kaul I, Sawchak S, Correll CU, Kakar R, Breier A, Zhu H, Miller AC, Paul SM, Brannan SK (2024b) Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-tropium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. *Lancet* 403:160-170.
- Keefe RSE, Fox KH, Harvey PD, Cucchiaro J, Sui C, Loebel A (2011) Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. *Schizophrenia Res* 125:161-168.
- Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh VV, Mahadik SP (2002) Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. *Schizophr Res* 58:1-10.
- Kim E, Howes OD, Veronese M, Beck K, Seo S, Park JW, Lee JS, Lee YS, Kwon JS (2017) Presynaptic dopamine capacity in patients with treatment-resistant schizophrenia taking clozapine: an [(18)F]DOPA PET study. *Neuropsychopharmacology* 42:941-950.
- Kim MK, Kim SH, Yu HS, Park HG, Kang UG, Ahn YM, Kim YS (2012) The effect of clozapine on the AMPK-ACC-CPT1 pathway in the rat frontal cortex. *Int J Neuropsychopharmacol* 15:907-917.
- Kimura H, Mori D, Aleksic B, Ozaki N (2021) Elucidation of molecular pathogenesis and drug development for psychiatric disorders from rare disease-susceptibility variants. *Neurosci Res* 170:24-31.
- Kingwell K (2024) FDA approves first schizophrenia drug with new mechanism of action since 1950s. *Nat Rev Drug Discov* 23:803.
- Kirkpatrick B, Luther L, Strauss GP (2023) Negative symptoms in the clinic: we treat what we can describe. *Br J Psychiatry* 223:271-272.
- Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR (2006) The NIMH-MATRICS consensus statement on negative symptoms. *Schizophr Bull* 32:214-219.
- Kopylov AT, Stepanov AA, Butkova TV, Malsagova KA, Zakharova NV, Kostyuk GP, Elmuratov AU, Kaysheva AL (2023) Consolidation of metabolomic, proteomic, and GWAS data in connective model of schizophrenia. *Sci Rep* 13:2139.
- Koskivi M, et al. (2024) Genetic contribution to microglial activation in schizophrenia. *Mol Psychiatry* 29:2622-2633.
- Kroken RA, Sommer IE, Steen VM, Dieset I, Johnsen E (2018) Constructing the immune signature of schizophrenia for clinical use and research; an integrative review translating descriptives into diagnostics. *Front Psychiatry* 9:753.
- Krystal JH, Kane JM, Correll CU, Walling DP, Leoni M, Duvvuri S, Patel S, Chang I, Iredale P, Frohlich L, Versavel S, Perry P, Sanchez R, Renger J (2022) Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial. *Lancet* 400:2210-2220.
- Lally J, Ajnakina O, Di Forti M, Trotta A, Demjaha A, Kolliakou A, Mondelli V, Reis Marques T, Pariante C, Dazzan P, Smerglia SS, Howes OD, David AS, MacCabe JH, Gaughran F, Murray RM (2016) Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. *Psychol Med* 46:3231-3240.
- Langmead CJ, et al. (2008) Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1. *Br J Pharmacol* 154:1104-1115.
- Law AJ, Deakin JF (2001) Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. *Neuroreport* 12:2971-2974.
- Lee JD, Coulthard LG, Woodruff TM (2019) Complement dysregulation in the central nervous system during development and disease. *Semin Immunol* 45:101340.
- Lewine R, Hart M (2020) Schizophrenia spectrum and other psychotic disorders. In: *Handbook of Clinical Neurology* (Lanzenberger R, Kranz GS, Savic I, eds), pp 315-333. Amsterdam: Elsevier.
- Liao Y, Goraya MU, Yuan X, Zhang B, Chiu SH, Chen JL (2019) Functional involvement of interferon-inducible transmembrane proteins in antiviral immunity. *Front Microbiol* 10:1097.
- Lim K, Yee JY, See YM, Ng BT, Zheng S, Tang C, Lencz T, Lee J, Lam M (2023) Deconstructing the genetic architecture of treatment-resistant schizophrenia in East Asian ancestry. *Asian J Psychiatr* 90:103826.
- Lin SH, Lee LT, Yang YK (2014) Serotonin and mental disorders: a concise review on molecular neuroimaging evidence. *Clin Psychopharmacol Neurosci* 12:196-202.
- Liu YU, Ying Y, Li Y, Eyo UB, Chen T, Zheng J, Umpierre AD, Zhu J, Bosco DB, Dong H, Wu LJ (2019) Neuronal network activity controls microglial process surveillance in awake mice via norepinephrine signaling. *Nat Neurosci* 22:1771-1781.




- Lodge DJ, Grace AA (2007) Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia. *J Neurosci* 27:11424-11430.
- Lodge DJ, Behrens MM, Grace AA (2009) A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia. *J Neurosci* 29:2344-2354.
- Luo A, Jung J, Longley M, Rosoff DB, Charlet K, Muench C, Lee J, Hodgkinson CA, Goldman D, Horvath S, Kaminsky ZA, Lohoff FW (2020) Epigenetic aging is accelerated in alcohol use disorder and regulated by genetic variation in APOL2. *Neuropsychopharmacology* 45:327-336.
- MacCabe JH, Wicks S, Löfving S, David AS, Berndtsson Å, Gustafsson JE, Allebeck P, Dalman C (2013) Decline in cognitive performance between ages 13 and 18 years and the risk for psychosis in adulthood: a Swedish longitudinal cohort study in males. *JAMA Psychiatry* 70:261-270.
- Macek TA, McCue M, Dong X, Hanson E, Goldsmith P, Affinito J, Mahabeshwarkar AR (2019) A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia. *Schizophr Res* 204:289-294.
- Maiza O, Mazoyer B, Hervé PY, Razafimandimby A, Dollfus S, Tzourio-Mazoyer N (2011) Reproducibility of fMRI activations during a story listening task in patients with schizophrenia. *Schizophr Res* 128:98-101.
- Meltzer HY, Rabinowitz J, Lee MA, Cola PA, Ranjan R, Findling RL, Thompson PA (1997) Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. *Am J Psychiatry* 154:475-482.
- McCleery A, Nuechterlein KH (2019) Cognitive impairment in psychotic illness: prevalence, profile of impairment, developmental course, and treatment considerations. *Dialogues Clin Neurosci* 21:239-248.
- McCutcheon RA, Keefe RSE, McGuire PK (2023) Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. *Mol Psychiatry* 28:1902-1918.
- Mecca AP, O'Dell RS, Sharp ES, Banks ER, Bartlett HH, Zhao W, Lipior S, Diepenbrock NG, Chen MK, Naganawa M, Toyonaga T, Nabulsi NB, Vander Wyk BC, Arnsten AFT, Huang Y, Carson RE, van Dyck CH (2022) Synaptic density and cognitive performance in Alzheimer's disease: a PET imaging study with  $[(11)\text{C}]\text{UCB-J}$ . *Alzheimers Dement* 18:2527-2536.
- Medina-Hernandez V, Ramos-Loyo J, Luquin S, Sanchez LF, Garcia-Estrada J, Navarro-Ruiz A (2007) Increased lipid peroxidation and neuron specific enolase in treatment refractory schizophrenics. *J Psychiatr Res* 41:652-658.
- Mena A, Ruiz-Salas JC, Puentes A, Dorado I, Ruiz-Veguilla M, De la Casa LG (2016) Reduced prepulse inhibition as a biomarker of schizophrenia. *Front Behav Neurosci* 10:202.
- Menniti FS, Chappie TA, Schmidt CJ (2021) PDE10A inhibitors-clinical failure or window into antipsychotic drug action? *Front Neurosci* 14:600178.
- Merritt JL 2nd, Norris M, Kanungo S (2018) Fatty acid oxidation disorders. *Ann Transl Med* 6:473.
- Misiak B, Stramecki F, Gaweda L, Prochwicz K, Sasiadek MM, Moustafa AA, Frydecka D (2018) Interactions between variation in candidate genes and environmental factors in the etiology of schizophrenia and bipolar disorder: a systematic review. *Mol Neurobiol* 55:5075-5100.
- Mitsushima D, Sano A, Takahashi T (2013) A cholinergic trigger drives learning-induced plasticity at hippocampal synapses. *Nat Commun* 4:2760.
- Miyazawa A, Kanahara N, Kogure M, Otsuka I, Okazaki S, Watanabe Y, Yamasaki F, Nakata Y, Oda Y, Hishimoto A, Iyo M (2022) A preliminary genetic association study of GAD1 and GABAB receptor genes in patients with treatment-resistant schizophrenia. *Mol Biol Rep* 49:2015-2024.
- Möller HJ, Jäger M, Riedel M, Obermeier M, Strauss A, Bottlender R (2010) The Munich 15-year follow-up study (MUFUSSAD) on first-hospitalized patients with schizophrenic or affective disorders: comparison of psychopathological and psychosocial course and outcome and prediction of chronicity. *Eur Arch Psychiatry Clin Neurosci* 260:367-384.
- Mondelli V, Di Forti M, Morgan BP, Murray RM, Pariante CM, Dazzan P (2020) Baseline high levels of complement component 4 predict worse clinical outcome at 1-year follow-up in first-episode psychosis. *Brain Behav Immun* 88:913-915.
- Mosolov SN, Yaltonskaya PA (2021) Primary and secondary negative symptoms in schizophrenia. *Front Psychiatry* 12:766692.
- Mouchlianitis E, Bloomfield MA, Law V, Beck K, Selvaraj S, Rasquinha N, Waldman A, Turkheimer FE, Egerton A, Stone J, Howes OD (2016) Treatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared To Treatment-Responsive. *Schizophr Bull* 42:744-752.
- Mukai Y, Lupinacci R, Marder S, Snow-Adami L, Voss T, Smith SM, Egan MF (2024) Effects of PDE10A inhibitor MK-8189 in people with an acute episode of schizophrenia: a randomized proof-of-concept clinical trial. *Schizophr Res* 270:37-43.
- Murray CJL, et al. (2020) Five insights from the Global Burden of Disease Study 2019. *Lancet* 396:1135-1159.
- Murthy V, Hanson E, Demartinis N, Asgharnejad M, Dong C, Evans R, Ge TT, Dunayevich E, Singh JB, Ratti E, Galderisi S (2024) INTERACT: a randomized phase 2 study of the DAAO inhibitor luvadaxistat in adults with schizophrenia. *Schizophr Res* 270:249-257.
- Nair PC, Chalker JM, McKinnon RA, Langmead CJ, Gregory KJ, Bastiampillai T (2022) Trace Amine-Associated Receptor 1 (TAAR1): molecular and clinical insights for the treatment of schizophrenia and related comorbidities. *ACS Pharmacol Transl Sci* 5:183-188.
- Nakamura T, Takata A (2023) The molecular pathology of schizophrenia: an overview of existing knowledge and new directions for future research. *Mol Psychiatry* 28:1868-1889.
- Nakazawa K, Sapkota K (2020) The origin of NMDA receptor hypofunction in schizophrenia. *Pharmacol Ther* 205:107426.
- Ngan ETC, Yatham LN, Ruth TJ, Liddle PF (2000) Decreased serotonin 2A receptor densities in neuroleptic-naïve patients with schizophrenia: a PET study using  $[18\text{F}]$  Setoperone. *Am J Psychiatry* 157:1016-1018.
- Nielsen RE, Levander S, Kjaersdam Telléus G, Jensen SO, Østergaard Christensen T, Leucht S (2015) Second-generation antipsychotic effect on cognition in patients with schizophrenia--a meta-analysis of randomized clinical trials. *Acta Psychiatr Scand* 131:185-196.
- Okada H, Hirano D, Taniguchi T (2021) Impact of negative symptom domains and other clinical characteristics on functional outcomes in patients with schizophrenia. *Schizophr Res Treatment* 2021:8864352.
- Pal MM (2021) Glutamate: the master neurotransmitter and its implications in chronic stress and mood disorders. *Front Hum Neurosci* 15:722323.
- Paul SM, Yohn SE, Popiolek M, Miller AC, Felder CC (2022) Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia. *Am J Psychiatry* 179:611-627.
- Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumham A, Hindley G, Beck K, Natesan S, Efthimiou O, Cipriani A, Howes OD (2020) Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. *Lancet Psychiatry* 7:64-77.
- Potkin SG, Kane JM, Correll CU, Lindenmayer JP, Agid O, Marder SR, Olsson M, Howes OD (2020) The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. *NPI Schizophr* 6:1.
- Priya A, Johar K, Wong-Riley MTT (2013) Specificity protein 4 functionally regulates the transcription of NMDA receptor subunits GluN1, GluN2A, and GluN2B. *Biochim Biophys Acta* 1833:2745-2756.
- Raux G, et al. (2007) Involvement of hyperproliferemia in cognitive and psychiatric features of the 22q11 deletion syndrome. *Hum Mol Genet* 16:83-91.
- Rebola N, Srikumar BN, Mülle C (2010) Activity-dependent synaptic plasticity of NMDA receptors. *J Physiol* 588:93-99.
- Remington G, Agid O, Foussias G, Fervaha G, Takeuchi H, Lee J, Hahn M (2015a) What does schizophrenia teach us about antipsychotics? *Can J Psychiatry* 60:S14-18.
- Remington G, Agid O, Foussias G, Fervaha G, Takeuchi H, Lee J, Hahn M, Cairns M (2015b) What does schizophrenia teach us about antipsychotics. *Can J Psychiatry* 60:S14-S18.
- Reske M, Kellermann T, Habel U, Jon Shah N, Backes V, von Wilmsdorff M, Stöcker T, Gaebel W, Schneider F (2007) Stability of emotional dysfunctions? A long-term fMRI study in first-episode schizophrenia. *J Psychiatr Res* 41:918-927.
- Ripke S, et al. (2013) Genome-wide association analysis identifies 13 new risk loci for schizophrenia. *Nat Genet* 45:1150-1159.
- Rosen C, Grossman LS, Harrow M, Bonner-Jackson A, Faull R (2011) Diagnostic and prognostic significance of Schneiderian first-rank symptoms: a 20-year longitudinal study of schizophrenia and bipolar disorder. *Compr Psychiatry* 52:126-131.
- Rosenbrock H, Desch M, Wunderlich G (2023) Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia. *Eur Arch Psychiatry Clin Neurosci* 273:1557-1566.
- Rossum RC, Hooker SA, O'Connor PJ, Crain AL, Sperl-Hillen JM (2022) Cardiovascular risk for patients with and without schizophrenia, schizoaffective disorder, or bipolar disorder. *J Am Heart Assoc* 11:e021444.
- Sakurai T, Gamo NJ (2019) Cognitive functions associated with developing prefrontal cortex during adolescence and developmental neuropsychiatric disorders. *Neurobiol Dis* 131:104322.
- Sanders AR, Drigalenko EI, Duan J, Moy W, Freda J, Göring HHH, Gejman PV (2017) Transcriptome sequencing study implicates immune-related genes differentially expressed in schizophrenia: new data and a meta-analysis. *Transl Psychiatry* 7:e1093.
- Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R, Ransohoff RM, Greenberg ME, Barres BA, Stevens B (2012) Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. *Neuron* 74:691-705.
- Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium (2011) Genome-wide association study identifies five new schizophrenia loci. *Nat Genet* 43:969-976.
- Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014) Biological insights from 108 schizophrenia-associated genetic loci. *Nature* 511:421-427.
- Schwartz TL, Sachdeva S, Stahl SM (2012) Glutamate neurocircuitry: theoretical underpinnings in schizophrenia. *Front Pharmacol* 3:195.
- Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N, Tooley K, Presumey J, Baum M, Van Doren V, Genovese G, Rose SA, Handsaker RE; Schizophrenia Working Group of the Psychiatric Genomics Consortium; Daly MJ, Carroll MC, Stevens B, McCarroll SA (2016) Schizophrenia risk from complex variation of complement component 4. *Nature* 530:177-183.
- Sellgren CM, Gracias J, Watmuff B, Biag JD, Thanos JM, Whittredge PB, Fu T, Worringer K, Brown HE, Wang J, Kaykas A, Karmacharya R, Goolod CP, Sheridan SD, Perlis RH (2019) Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning. *Nat Neurosci* 22:374-385.


- Severance EG, Yolken RH (2016) Role of immune and autoimmune dysfunction in schizophrenia. *Handb Behav Neurosci* 23:501-516.
- Sheffield JM, Karcher NR, Barch DM (2018) Cognitive deficits in psychotic disorders: a lifespan perspective. *Neuropsychol Rev* 28:509-533.
- Shin JH, Adrover MF, Wess J, Alvarez VA (2015) Muscarinic regulation of dopamine and glutamate transmission in the nucleus accumbens. *Proc Natl Acad Sci U S A* 112:8124-8129.
- Shiraishi E, Suzuki K, Harada A, Suzuki N, Kimura H (2016) The phosphodiesterase 10A selective inhibitor TAK-063 improves cognitive functions associated with schizophrenia in rodent models. *J Pharmacol Exp Ther* 356:587-595.
- Siafis S, et al. (2024) Trace amine-associated receptor 1 (TAAR1) agonism for psychosis: a living systematic review and meta-analysis of human and non-human data. *Wellcome Open Res* 9:182.
- Siegel BI, Sengupta EJ, Edelson JR, Lewis DA, Volk DW (2014) Elevated viral restriction factor levels in cortical blood vessels in schizophrenia. *Biol Psychiatry* 76:160-167.
- Singh T, et al. (2022) Rare coding variants in ten genes confer substantial risk for schizophrenia. *Nature* 604:509-516.
- Skiba RM, Chinchani AM, Menon M, Lepage M, Lavigne KM, Malla A, Joobar R, Goldberg JO, Heinrichs RW, Castle DJ, Burns A, Best MW, Rossell SL, Walther S, Woodward TS (2024) Overlap between individual differences in cognition and symptoms of schizophrenia. *Schizophr Res* 270:220-228.
- Solmi M, Seitidis G, Mavridis D, Correll CU, Dragioti E, Guimond S, Tuominen L, Dargel A, Carvalho AF, Fornaro M, Maes M, Monaco F, Song M, Il Shin J, Cortese S (2023) Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the Global Burden of Disease (GBD) 2019. *Mol Psychiatry* 28:5319-5327.
- Sommer IE, van Westrhenen R, Begemann MJ, de Witte LD, Leucht S, Kahn RS (2014) Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. *Schizophr Bull* 40:181-191.
- Soteros BM, Sia GM (2022) Complement and microglia dependent synapse elimination in brain development. *WIREs Mech Dis* 14:e1545.
- Stahl SM (2018) Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate. *CNS Spectr* 23:187-191.
- Starzer M, Hansen HG, Hjorthøj C, Albert N, Nordentoft M, Madsen T (2023) 20-year trajectories of positive and negative symptoms after the first psychotic episode in patients with schizophrenia spectrum disorder: results from the OPUS study. *World Psychiatry* 22:424-432.
- Stefansson H, et al. (2009) Common variants conferring risk of schizophrenia. *Nature* 460:744-747.
- Stephan KE, Friston KJ, Frith CD (2009) Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring. *Schizophr Bull* 35:509-527.
- Stogios N, Gdanski A, Gerretsen P, Chintoh AF, Graff-Guerrero A, Rajji TK, Remington G, Hahn MK, Agarwal SM (2021) Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health. *NPJ Schizophr* 7:22.
- Takahashi S, Cui YH, Han YH, Fargnass JA, Galloway B, Shen YC, Kojima T, Uchiyama M, Faraone SV, Tsuang MT (2008) Association of SNPs and haplotypes in APOL1, 2 and 4 with schizophrenia. *Schizophr Res* 104:153-164.
- Takeuchi H, Siu C, Remington G, Fervaha G, Zipursky RB, Foussias G, Agid O (2019) Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. *Neuropsychopharmacology* 44:1036-1042.
- Tanahashi S, Yamamura S, Nakagawa M, Motomura E, Okada M (2012) Clozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes. *Br J Pharmacol* 165:1543-1555.
- Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, Hansen KB, Yuan H, Myers SJ, Dingledine R (2010) Glutamate receptor ion channels: structure, regulation, and function. *Pharmacol Rev* 62:405-496.
- Trepanier MO, Hopperton KE, Mizrahi R, Mechawar N, Bazinet RP (2016) Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review. *Mol Psychiatry* 21:1009-1026.
- Trubetskoy V, et al. (2022) Mapping genomic loci implicates genes and synaptic biology in schizophrenia. *Nature* 604:502-508.
- Tzavara ET, Bymaster FP, Davis RJ, Wade MR, Perry KW, Wess J, McKinzie DL, Felder C, Nomikos GG (2004) M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies. *FASEB J* 18:1410-1412.
- Ueno F, Nakajima S, Iwata Y, Honda S, Torres-Carmona E, Mar W, Tsugawa S, Truong P, Plitman E, Noda Y, Mimura M, Sailasuta N, Mikkelsen M, Edden RAE, De Luca V, Remington G, Gerretsen P, Graff-Guerrero A (2022) Gamma-aminobutyric acid (GABA) levels in the midcingulate cortex and clozapine response in patients with treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy ((1)H-MRS) study. *Psychiatry Clin Neurosci* 76:587-594.
- Uranova NA, Vikhreva OV, Rakhmanova VI, Orlovskaya DD (2020) Dystrophy of oligodendrocytes and adjacent microglia in prefrontal gray matter in schizophrenia. *Front Psychiatry* 11:204.
- Veerhuis R, Nielsen HM, Tenner AJ (2011) Complement in the brain. *Mol Immunol* 48:1592-1603.
- Veerman SR, Schulte PF, Begemann MJ, Engelsbel F, de Haan L (2014) Clozapine augmented with glutamate modulators in refractory schizophrenia: a review and metaanalysis. *Pharmacopsychiatry* 47:185-194.
- Velligan DL, Mahurin RK, Diamond PL, Hazleton BC, Eckert SL, Miller AL (1997) The functional significance of symptomatology and cognitive function in schizophrenia. *Schizophr Res* 25:21-31.
- Verdolini N, et al. (2022) Prodromal phase: differences in prodromal symptoms, risk factors and markers of vulnerability in first episode mania versus first episode psychosis with onset in late adolescence or adulthood. *Acta Psychiatr Scand* 146:36-50.
- Virmani A, Pinto L, Bauermann O, Zerelli S, Diedenhofen A, Binienda ZK, Ali SF, van der Leij FR (2015) The carnitine palmitoyl transferase (CPT) system and possible relevance for neuropsychiatric and neurological conditions. *Mol Neurobiol* 52:826-836.
- Volk DW, Chitrapu A, Edelson JR, Roman KM, Moroco AE, Lewis DA (2015) Molecular mechanisms and timing of cortical immune activation in schizophrenia. *Am J Psychiatry* 172:1112-1121.
- Vorstman JA, Turetsky BJ, Sijmens-Morcus ME, de Sain MG, Dorland B, Sprong M, Rappaport EF, Beemer FA, Emanuel BS, Kahn RS, van Engeland H, Kemner C (2009) Proline affects brain function in 22q11DS children with the low activity COMT 158 allele. *Neuropsychopharmacology* 34:739-746.
- Walling DP, Banerjee A, Dawra V, Boyer S, Schmidt CJ, DeMartini N (2019) Phosphodiesterase 10A inhibitor monotherapy is not an effective treatment of acute schizophrenia. *J Clin Psychopharm* 39:575-582.
- Wang KS, Liu XF, Aragao N (2010) A genome-wide meta-analysis identifies novel loci associated with schizophrenia and bipolar disorder. *Schizophr Res* 124:192-199.
- Wang X, Chang Z, Wang R (2023) Opposite effects of positive and negative symptoms on resting-state brain networks in schizophrenia. *Commun Biol* 6:279.
- Wei W, Zhang H, Cheng B, Qin X, He D, Zhang N, Zhao Y, Cai Q, Shi S, Chu X, Wen Y, Liu H, Jia Y, Zhang F (2023) Identification of novel functional brain proteins for treatment-resistant schizophrenia: based on a proteome-wide association study. *Eur Psychiatry* 66:e33.
- Weickert CS, Fung SJ, Catts VS, Schofield PR, Allen KM, Moore LT, Newell KA, Pellen D, Huang XF, Catts SV, Weickert TW (2013) Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia. *Mol Psychiatry* 18:1185-1192.
- White CJ, Lee J, Choi J, Chu T, Scafidi S, Wolfgang MJ (2020) Determining the bioenergetic capacity for fatty acid oxidation in the mammalian nervous system. *Mol Cell Biol* 40:e00037-20.
- Wu Y, Wang Z, Hu H, Wu T, Alalab AAA, Sun Z, Wang Y, Cui G, Cong W, Li C, Li P (2024) Identification of immune-related gene signature in schizophrenia. *Actas Esp Psiquiatr* 52:276-288.
- Xie Z, Jones A, Deenen JT, Hur SK, Bankaitis VA (2016) Inborn errors of long-chain fatty acid beta-oxidation link neural stem cell self-renewal to autism. *Cell Rep* 14:991-999.
- Yamamori H, Hashimoto R, Fujita Y, Numata S, Yasuda Y, Fujimoto M, Ohi K, Umeda-Yano S, Ito A, Ohmori T, Hashimoto K, Takeda M (2014) Changes in plasma D-serine, L-serine, and glycine levels in treatment-resistant schizophrenia before and after clozapine treatment. *Neurosci Lett* 582:93-98.
- Yang VX, Sin Fai Lam CC, Kane JPM (2023) Cognitive impairment and development of dementia in very late-onset schizophrenia-like psychosis: a systematic review. *Ir J Psychol Med* 40:616-628.
- Yilmaz M, Yalcin E, Presumey J, Aw E, Ma M, Whelan CW, Stevens B, McCarroll SA, Carroll MC (2021) Overexpression of schizophrenia susceptibility factor human complement C4A promotes excessive synaptic loss and behavioral changes in mice. *Nat Neurosci* 24:214-224.
- Yohn SE, Weiden PJ, Felder CC, Stahl SM (2022) Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic. *Trends Pharmacol Sci* 43:1098-1112.
- Yuen EY, Zhong P, Yan Z (2010) Homeostatic regulation of glutamatergic transmission by dopamine D4 receptors. *Proc Natl Acad Sci U S A* 107:22308-22313.
- Yuen EY, Jiang Q, Chen P, Feng J, Yan Z (2008) Activation of 5-HT2A/C receptors counteracts 5-HT1A regulation of n-methyl-D-aspartate receptor channels in pyramidal neurons of prefrontal cortex. *J Biol Chem* 283:17194-17204.
- Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU (2013) Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. *Int J Neuropsychopharmacol* 16:1205-1218.
- Zhao X, Li J, Winkler CA, An P, Guo JT (2018) IFITM genes, variants, and their roles in the control and pathogenesis of viral infections. *Front Microbiol* 9:3228.
- Zhou X, Nie Z, Roberts A, Zhang D, Sebat J, Malhotra D, Kelsoe JR, Geyer MA (2010) Reduced NMDAR1 expression in the Sp4 hypomorphic mouse may contribute to endophenotypes of human psychiatric disorders. *Hum Mol Genet* 19:3797-3805.
- Zhuo C, Tian H, Song X, Jiang D, Chen G, Cai Z, Ping J, Cheng L, Zhou C, Chen C (2023) Microglia and cognitive impairment in schizophrenia: translating scientific progress into novel therapeutic interventions. *Schizophrenia (Heidelberg)* 9:42.
- Zhuo C, Hou W, Li G, Mao F, Li S, Lin X, Jiang D, Xu Y, Tian H, Wang W, Cheng L (2019) The genomics of schizophrenia: Shortcomings and solutions. *Prog Neuropsychopharmacol Biol Psychiatry* 93:71-76.
- Zilberg G, Parpounas AK, Warren AL, Yang S, Wacker D (2024) Molecular basis of human trace amine-associated receptor 1 activation. *Nat Commun* 15:108.
- Zoghbi AW, Dhindsa RS, Goldberg TE, Mehrizade A, Motelow JE, Wang X, Alkelai A, Harms MB, Lieberman JA, Markx S, Goldstein DB (2021) High-impact rare genetic variants in severe schizophrenia. *Proc Natl Acad Sci U S A* 118:e2112560118.

C-Editors: Zhao M, Liu WJ, Qiu Y; T-Editor: Zhou H

Table 1 A list of companies with Phase 2 or higher development with active indications for treatment of schizophrenia

| Drug name                                              | Originator company                      | Active companies                        | Active indications                                             | Target-based actions                                                                                                                 | Highest status   | Technologies                                                                                       | Structure                                                                             | Status                                                                                         |
|--------------------------------------------------------|-----------------------------------------|-----------------------------------------|----------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|------------------|----------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
| Evenamide                                              | Newron Pharmaceuticals SpA              | Newron Pharmaceuticals SpA              | Bipolar disorder; mania; schizophrenia                         | Sodium channel inhibitor; voltage gated sodium channel inhibitor                                                                     | Phase 3 Clinical | Capsule formulation; oral formulation; small molecule therapeutic                                  |    | Under development as adjuvant for treatment-resistant schizophrenia (NCT04461119)              |
| Iclepertin                                             | Boehringer Ingelheim International GmbH | Boehringer Ingelheim International GmbH | Alzheimer's disease; cognitive disorder; schizophrenia         | Beta amyloid synthesis inhibitor; glycine transporter-1 inhibitor                                                                    | Phase 3 Clinical | Film coating; formulation powder; oral formulation; small molecule therapeutic; tablet formulation |    | Under development for cognitive impairment associated with schizophrenia (NCT05211947)         |
| Emraclidine                                            | Pfizer Inc                              | Cerevel Therapeutics Inc                | Alzheimer's disease; psychotic disorder; schizophrenia         | Muscarinic M4 receptor modulator                                                                                                     | Phase 2 Clinical | Oral formulation; quick release formulation; small molecule therapeutic; tablet formulation        |    | Under development for psychosis (NCT05443724)                                                  |
| Xanomeline + trospium chloride (schizophrenia), karuna | Karuna Therapeutics Inc                 | Karuna Therapeutics Inc; Zai Lab Ltd.   | Alzheimer's disease; dementia related psychosis; schizophrenia | Muscarinic M1 receptor agonist; muscarinic M2 receptor antagonist; muscarinic M3 receptor antagonist; muscarinic M4 receptor agonist | Registered       | Capsule formulation; drug combination; oral formulation; small molecule therapeutic                |  | FDA approved Karuna/Bristol Myers Squibb's KarXT (Cobenfy) for schizophrenia in September 2024 |

|             |                                          |                                        |                                                                                            |                                                                                             |                  |                                                                                                                               |                                                                                       |                                                                                        |
|-------------|------------------------------------------|----------------------------------------|--------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|------------------|-------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| ALTO-101    | Alto Neuroscience Inc                    | Alto Neuroscience Inc; MEDRx Co., Ltd. | Cognitive disorder; neurodegenerative disease; psychiatric disorder; schizophrenia         | PDE 4 inhibitor                                                                             | Phase 2 Clinical | Small molecule therapeutic; transdermal formulation                                                                           | N/A                                                                                   | Under development for cognitive impairment associated with schizophrenia (NCT06502964) |
| CPL-500036  | Celon Pharma SP                          | Celon Pharma SP                        | Huntington's chorea; movement disorder; Parkinson's disease; schizophrenia                 | PDE 10 inhibitor                                                                            | Phase 2 Clinical | Capsule formulation; once daily formulation; oral formulation; small molecule therapeutic                                     |    | Under development for the treatment of acute schizophrenia (NCT05278156)               |
| MK-8189     | Merck & Co., Inc., Rahway, NJ, USA       | Merck & Co., Inc., Rahway, NJ, USA     | Alzheimer's disease; bipolar I disorder; schizoaffective disorder; schizophrenia           | PDE 10 inhibitor                                                                            | Phase 2 Clinical | Once daily formulation; oral controlled release formulation; oral formulation; small molecule therapeutic; tablet formulation |    | Under development for the treatment of acute schizophrenia (NCT05406440)               |
| ANAVEX 3-71 | Israel Institute for Biological Research | Anavex Life Sciences Corp              | Alzheimer's disease; frontotemporal dementia; Parkinson's disease; schizophrenia           | Amyloid- $\beta$ modulator; muscarinic M1 receptor agonist; opioid receptor sigma agonist 1 | Phase 2 Clinical | Oral formulation; small molecule therapeutic                                                                                  |   | Under development for schizophrenia (NCT06245213).                                     |
| Ulotaront   | Sumitomo Pharma America Inc              | Otsuka Pharmaceutical Co., Ltd.        | Generalized anxiety disorder; major depressive disorder; psychotic disorder; schizophrenia | 5-HT 1a receptor agonist; trace amine associated receptor 1 agonist                         | Phase 3 Clinical | Oral formulation; small molecule therapeutic; tablet formulation                                                              |  | Phase 3 studies completed (NCT04072354, NCT04092686), No further study initiated.      |

|         |                |                         |                                                                                                                  |                                                                                          |                  |                                                                                                            |                                                                                     |                                                                                        |
|---------|----------------|-------------------------|------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|------------------|------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| RL-007  | Allergan plc   | Recognify Life Sciences | Alzheimer's disease; anxiety disorders; cognitive disorder; neuropathic pain; schizophrenia                      | GABA B receptor agonist; NMDA receptor agonist; nicotinic acetylcholine receptor agonist | Phase 2 Clinical | Oral formulation; small molecule therapeutic                                                               |  | Under development for cognitive impairment associated with schizophrenia (NCT05686239) |
| SPG-302 | Spinogenix Inc | Spinogenix Inc          | Alzheimer's disease; amyotrophic lateral sclerosis; neurodegenerative disease; schizophrenia; spinal cord injury | NA                                                                                       | Phase 2 Clinical | Once daily formulation; oral formulation; small molecule therapeutic; synthetic method; tablet formulation | N/A                                                                                 | Under development for Schizophrenia (NCT06442462)                                      |